WO2022161893A1 - Buccal mucoadhesive gel containing probiotics for use in the prevention and treatment of periodontal diseases. - Google Patents
Buccal mucoadhesive gel containing probiotics for use in the prevention and treatment of periodontal diseases. Download PDFInfo
- Publication number
- WO2022161893A1 WO2022161893A1 PCT/EP2022/051430 EP2022051430W WO2022161893A1 WO 2022161893 A1 WO2022161893 A1 WO 2022161893A1 EP 2022051430 W EP2022051430 W EP 2022051430W WO 2022161893 A1 WO2022161893 A1 WO 2022161893A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- amount
- viscosity
- lactobacilli
- gel
- mixture
- Prior art date
Links
- 239000006041 probiotic Substances 0.000 title claims abstract description 90
- 235000018291 probiotics Nutrition 0.000 title claims abstract description 89
- 230000003232 mucoadhesive effect Effects 0.000 title claims abstract description 51
- 238000011282 treatment Methods 0.000 title claims abstract description 22
- 230000002265 prevention Effects 0.000 title claims abstract description 10
- 208000028169 periodontal disease Diseases 0.000 title description 6
- 239000000499 gel Substances 0.000 claims abstract description 156
- 210000000214 mouth Anatomy 0.000 claims abstract description 21
- 238000002360 preparation method Methods 0.000 claims abstract description 19
- 238000000034 method Methods 0.000 claims abstract description 12
- 230000008569 process Effects 0.000 claims abstract description 7
- 230000007170 pathology Effects 0.000 claims abstract description 5
- 239000000203 mixture Substances 0.000 claims description 169
- VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 claims description 48
- 230000000529 probiotic effect Effects 0.000 claims description 39
- 241000186660 Lactobacillus Species 0.000 claims description 38
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 claims description 31
- 239000007864 aqueous solution Substances 0.000 claims description 28
- 240000002605 Lactobacillus helveticus Species 0.000 claims description 26
- 241000218588 Lactobacillus rhamnosus Species 0.000 claims description 24
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 claims description 24
- 239000000377 silicon dioxide Substances 0.000 claims description 24
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 claims description 23
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 claims description 23
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 claims description 23
- 239000003795 chemical substances by application Substances 0.000 claims description 21
- 239000000243 solution Substances 0.000 claims description 20
- 201000001245 periodontitis Diseases 0.000 claims description 19
- 150000002148 esters Chemical class 0.000 claims description 18
- 241000186605 Lactobacillus paracasei Species 0.000 claims description 17
- WWZKQHOCKIZLMA-UHFFFAOYSA-N octanoic acid Chemical compound CCCCCCCC(O)=O WWZKQHOCKIZLMA-UHFFFAOYSA-N 0.000 claims description 17
- 239000001856 Ethyl cellulose Substances 0.000 claims description 16
- GHVNFZFCNZKVNT-UHFFFAOYSA-N decanoic acid Chemical compound CCCCCCCCCC(O)=O GHVNFZFCNZKVNT-UHFFFAOYSA-N 0.000 claims description 16
- 235000019325 ethyl cellulose Nutrition 0.000 claims description 16
- 229920001249 ethyl cellulose Polymers 0.000 claims description 16
- 229940049654 glyceryl behenate Drugs 0.000 claims description 15
- 239000000227 bioadhesive Substances 0.000 claims description 14
- ZZSNKZQZMQGXPY-UHFFFAOYSA-N Ethyl cellulose Chemical compound CCOCC1OC(OC)C(OCC)C(OCC)C1OC1C(O)C(O)C(OC)C(CO)O1 ZZSNKZQZMQGXPY-UHFFFAOYSA-N 0.000 claims description 13
- 239000002270 dispersing agent Substances 0.000 claims description 13
- OKMWKBLSFKFYGZ-UHFFFAOYSA-N 1-behenoylglycerol Chemical compound CCCCCCCCCCCCCCCCCCCCCC(=O)OCC(O)CO OKMWKBLSFKFYGZ-UHFFFAOYSA-N 0.000 claims description 12
- 241000186000 Bifidobacterium Species 0.000 claims description 12
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 12
- -1 polyoxy Polymers 0.000 claims description 11
- 240000001929 Lactobacillus brevis Species 0.000 claims description 9
- 235000013967 Lactobacillus helveticus Nutrition 0.000 claims description 9
- 229940054346 lactobacillus helveticus Drugs 0.000 claims description 9
- 239000005632 Capric acid (CAS 334-48-5) Substances 0.000 claims description 8
- 239000005635 Caprylic acid (CAS 124-07-2) Substances 0.000 claims description 8
- 206010061218 Inflammation Diseases 0.000 claims description 8
- 208000002925 dental caries Diseases 0.000 claims description 8
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 8
- 230000004054 inflammatory process Effects 0.000 claims description 8
- 229920002678 cellulose Polymers 0.000 claims description 7
- 239000001913 cellulose Substances 0.000 claims description 7
- 235000010980 cellulose Nutrition 0.000 claims description 7
- 235000014113 dietary fatty acids Nutrition 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 239000000194 fatty acid Substances 0.000 claims description 7
- 229930195729 fatty acid Natural products 0.000 claims description 7
- 150000004665 fatty acids Chemical class 0.000 claims description 7
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 claims description 6
- 229920001817 Agar Polymers 0.000 claims description 6
- WHNWPMSKXPGLAX-UHFFFAOYSA-N N-Vinyl-2-pyrrolidone Chemical compound C=CN1CCCC1=O WHNWPMSKXPGLAX-UHFFFAOYSA-N 0.000 claims description 6
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims description 6
- 235000021355 Stearic acid Nutrition 0.000 claims description 6
- 235000010489 acacia gum Nutrition 0.000 claims description 6
- 239000008272 agar Substances 0.000 claims description 6
- 235000010443 alginic acid Nutrition 0.000 claims description 6
- 229920000615 alginic acid Polymers 0.000 claims description 6
- 239000000440 bentonite Substances 0.000 claims description 6
- 229910000278 bentonite Inorganic materials 0.000 claims description 6
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 claims description 6
- 239000001768 carboxy methyl cellulose Substances 0.000 claims description 6
- 208000035475 disorder Diseases 0.000 claims description 6
- 235000011187 glycerol Nutrition 0.000 claims description 6
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 claims description 6
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 claims description 6
- 229960002446 octanoic acid Drugs 0.000 claims description 6
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 claims description 6
- 229920000036 polyvinylpyrrolidone Polymers 0.000 claims description 6
- 229940069328 povidone Drugs 0.000 claims description 6
- 239000008117 stearic acid Substances 0.000 claims description 6
- 239000001993 wax Substances 0.000 claims description 6
- 241001608472 Bifidobacterium longum Species 0.000 claims description 5
- 241000186604 Lactobacillus reuteri Species 0.000 claims description 5
- 241000194020 Streptococcus thermophilus Species 0.000 claims description 5
- 208000007565 gingivitis Diseases 0.000 claims description 5
- 238000003756 stirring Methods 0.000 claims description 5
- 208000003265 stomatitis Diseases 0.000 claims description 5
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 claims description 4
- 229920002472 Starch Polymers 0.000 claims description 4
- 239000000284 extract Substances 0.000 claims description 4
- 150000002334 glycols Chemical class 0.000 claims description 4
- 125000005842 heteroatom Chemical group 0.000 claims description 4
- 239000008107 starch Substances 0.000 claims description 4
- 235000019698 starch Nutrition 0.000 claims description 4
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical class CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 claims description 3
- 239000000263 2,3-dihydroxypropyl (Z)-octadec-9-enoate Substances 0.000 claims description 3
- RZRNAYUHWVFMIP-GDCKJWNLSA-N 3-oleoyl-sn-glycerol Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@H](O)CO RZRNAYUHWVFMIP-GDCKJWNLSA-N 0.000 claims description 3
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 claims description 3
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 claims description 3
- 229920002134 Carboxymethyl cellulose Polymers 0.000 claims description 3
- 229920001661 Chitosan Polymers 0.000 claims description 3
- 229920001353 Dextrin Polymers 0.000 claims description 3
- 239000004375 Dextrin Substances 0.000 claims description 3
- 108010010803 Gelatin Proteins 0.000 claims description 3
- 229920001503 Glucan Polymers 0.000 claims description 3
- 229920000084 Gum arabic Polymers 0.000 claims description 3
- SHBUUTHKGIVMJT-UHFFFAOYSA-N Hydroxystearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OO SHBUUTHKGIVMJT-UHFFFAOYSA-N 0.000 claims description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 claims description 3
- 239000004166 Lanolin Substances 0.000 claims description 3
- 240000006240 Linum usitatissimum Species 0.000 claims description 3
- 235000004431 Linum usitatissimum Nutrition 0.000 claims description 3
- 208000006389 Peri-Implantitis Diseases 0.000 claims description 3
- 229920000148 Polycarbophil calcium Polymers 0.000 claims description 3
- 229920002125 Sokalan® Polymers 0.000 claims description 3
- 229930006000 Sucrose Natural products 0.000 claims description 3
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 claims description 3
- 229920002000 Xyloglucan Polymers 0.000 claims description 3
- 239000000205 acacia gum Substances 0.000 claims description 3
- 239000001785 acacia senegal l. willd gum Substances 0.000 claims description 3
- DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 3
- 230000001070 adhesive effect Effects 0.000 claims description 3
- 229940023476 agar Drugs 0.000 claims description 3
- 229940072056 alginate Drugs 0.000 claims description 3
- 239000000783 alginic acid Substances 0.000 claims description 3
- 229960001126 alginic acid Drugs 0.000 claims description 3
- 150000004781 alginic acids Chemical class 0.000 claims description 3
- 238000011166 aliquoting Methods 0.000 claims description 3
- 125000005907 alkyl ester group Chemical class 0.000 claims description 3
- 125000000217 alkyl group Chemical group 0.000 claims description 3
- 235000013871 bee wax Nutrition 0.000 claims description 3
- 239000012166 beeswax Substances 0.000 claims description 3
- 229940092782 bentonite Drugs 0.000 claims description 3
- 229940004120 bifidobacterium infantis Drugs 0.000 claims description 3
- 229940009291 bifidobacterium longum Drugs 0.000 claims description 3
- 239000011575 calcium Substances 0.000 claims description 3
- 229910052791 calcium Inorganic materials 0.000 claims description 3
- 235000010948 carboxy methyl cellulose Nutrition 0.000 claims description 3
- 239000008112 carboxymethyl-cellulose Substances 0.000 claims description 3
- 235000010418 carrageenan Nutrition 0.000 claims description 3
- 239000000679 carrageenan Substances 0.000 claims description 3
- 229920001525 carrageenan Polymers 0.000 claims description 3
- 229940113118 carrageenan Drugs 0.000 claims description 3
- 239000004359 castor oil Chemical class 0.000 claims description 3
- 235000019438 castor oil Nutrition 0.000 claims description 3
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 3
- 229940045110 chitosan Drugs 0.000 claims description 3
- 238000001816 cooling Methods 0.000 claims description 3
- 235000019425 dextrin Nutrition 0.000 claims description 3
- 239000002552 dosage form Substances 0.000 claims description 3
- 235000004426 flaxseed Nutrition 0.000 claims description 3
- 229920000159 gelatin Polymers 0.000 claims description 3
- 239000008273 gelatin Substances 0.000 claims description 3
- 229940014259 gelatin Drugs 0.000 claims description 3
- 235000019322 gelatine Nutrition 0.000 claims description 3
- 235000011852 gelatine desserts Nutrition 0.000 claims description 3
- 229960005150 glycerol Drugs 0.000 claims description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Chemical class CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims description 3
- 229940072106 hydroxystearate Drugs 0.000 claims description 3
- 235000019388 lanolin Nutrition 0.000 claims description 3
- 229940039717 lanolin Drugs 0.000 claims description 3
- 239000000787 lecithin Substances 0.000 claims description 3
- 235000010445 lecithin Nutrition 0.000 claims description 3
- 239000007788 liquid Substances 0.000 claims description 3
- RZRNAYUHWVFMIP-UHFFFAOYSA-N monoelaidin Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC(O)CO RZRNAYUHWVFMIP-UHFFFAOYSA-N 0.000 claims description 3
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 3
- 150000002943 palmitic acids Chemical class 0.000 claims description 3
- 150000003904 phospholipids Chemical class 0.000 claims description 3
- 229950005134 polycarbophil Drugs 0.000 claims description 3
- 229920002689 polyvinyl acetate Polymers 0.000 claims description 3
- 239000011118 polyvinyl acetate Substances 0.000 claims description 3
- 229940075065 polyvinyl acetate Drugs 0.000 claims description 3
- 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 claims description 3
- 229920001027 sodium carboxymethylcellulose Polymers 0.000 claims description 3
- 239000005720 sucrose Substances 0.000 claims description 3
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 claims description 3
- 239000008158 vegetable oil Substances 0.000 claims description 3
- 239000000230 xanthan gum Substances 0.000 claims description 3
- 229920001285 xanthan gum Polymers 0.000 claims description 3
- 235000010493 xanthan gum Nutrition 0.000 claims description 3
- 229940082509 xanthan gum Drugs 0.000 claims description 3
- UHVMMEOXYDMDKI-JKYCWFKZSA-L zinc;1-(5-cyanopyridin-2-yl)-3-[(1s,2s)-2-(6-fluoro-2-hydroxy-3-propanoylphenyl)cyclopropyl]urea;diacetate Chemical compound [Zn+2].CC([O-])=O.CC([O-])=O.CCC(=O)C1=CC=C(F)C([C@H]2[C@H](C2)NC(=O)NC=2N=CC(=CC=2)C#N)=C1O UHVMMEOXYDMDKI-JKYCWFKZSA-L 0.000 claims description 3
- 241000149420 Bothrometopus brevis Species 0.000 claims description 2
- 240000006024 Lactobacillus plantarum Species 0.000 claims description 2
- 241000186869 Lactobacillus salivarius Species 0.000 claims description 2
- 239000000853 adhesive Substances 0.000 claims description 2
- 241000894006 Bacteria Species 0.000 description 40
- 238000009472 formulation Methods 0.000 description 23
- 230000001580 bacterial effect Effects 0.000 description 15
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 12
- 239000000120 Artificial Saliva Substances 0.000 description 10
- 239000000725 suspension Substances 0.000 description 10
- 102000015728 Mucins Human genes 0.000 description 9
- 108010063954 Mucins Proteins 0.000 description 9
- 244000005700 microbiome Species 0.000 description 8
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 8
- 241001465754 Metazoa Species 0.000 description 7
- 230000009286 beneficial effect Effects 0.000 description 7
- 238000012360 testing method Methods 0.000 description 7
- 230000035899 viability Effects 0.000 description 7
- 241000699670 Mus sp. Species 0.000 description 6
- 239000003085 diluting agent Substances 0.000 description 6
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 6
- 238000011084 recovery Methods 0.000 description 6
- 239000011780 sodium chloride Substances 0.000 description 6
- 241000736262 Microbiota Species 0.000 description 5
- 238000004458 analytical method Methods 0.000 description 5
- 230000008901 benefit Effects 0.000 description 5
- 210000000988 bone and bone Anatomy 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- 235000013957 Lactobacillus brevis Nutrition 0.000 description 4
- 244000052616 bacterial pathogen Species 0.000 description 4
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 4
- 238000000338 in vitro Methods 0.000 description 4
- 229940111688 monobasic potassium phosphate Drugs 0.000 description 4
- 235000019796 monopotassium phosphate Nutrition 0.000 description 4
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 4
- 230000001225 therapeutic effect Effects 0.000 description 4
- 241001134770 Bifidobacterium animalis Species 0.000 description 3
- 102000004190 Enzymes Human genes 0.000 description 3
- 108090000790 Enzymes Proteins 0.000 description 3
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- 102000003896 Myeloperoxidases Human genes 0.000 description 3
- 108090000235 Myeloperoxidases Proteins 0.000 description 3
- 208000025157 Oral disease Diseases 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000003462 bioceramic Substances 0.000 description 3
- 150000001875 compounds Chemical class 0.000 description 3
- 229940061607 dibasic sodium phosphate Drugs 0.000 description 3
- 238000010790 dilution Methods 0.000 description 3
- 239000012895 dilution Substances 0.000 description 3
- 239000000796 flavoring agent Substances 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 239000008240 homogeneous mixture Substances 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000004310 lactic acid Substances 0.000 description 3
- 235000014655 lactic acid Nutrition 0.000 description 3
- 244000000010 microbial pathogen Species 0.000 description 3
- 208000030194 mouth disease Diseases 0.000 description 3
- 244000052769 pathogen Species 0.000 description 3
- 239000000546 pharmaceutical excipient Substances 0.000 description 3
- 210000003296 saliva Anatomy 0.000 description 3
- 238000000926 separation method Methods 0.000 description 3
- 238000013207 serial dilution Methods 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- 241001024600 Aggregatibacter Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 208000035143 Bacterial infection Diseases 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- WQZGKKKJIJFFOK-QTVWNMPRSA-N D-mannopyranose Chemical compound OC[C@H]1OC(O)[C@@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-QTVWNMPRSA-N 0.000 description 2
- 208000002064 Dental Plaque Diseases 0.000 description 2
- MHAJPDPJQMAIIY-UHFFFAOYSA-N Hydrogen peroxide Chemical compound OO MHAJPDPJQMAIIY-UHFFFAOYSA-N 0.000 description 2
- 239000001888 Peptone Substances 0.000 description 2
- 108010080698 Peptones Proteins 0.000 description 2
- 241000605862 Porphyromonas gingivalis Species 0.000 description 2
- 241001135223 Prevotella melaninogenica Species 0.000 description 2
- 239000003242 anti bacterial agent Substances 0.000 description 2
- 229940088710 antibiotic agent Drugs 0.000 description 2
- 208000022362 bacterial infectious disease Diseases 0.000 description 2
- 230000037396 body weight Effects 0.000 description 2
- 239000001506 calcium phosphate Substances 0.000 description 2
- 239000005018 casein Substances 0.000 description 2
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 2
- 235000021240 caseins Nutrition 0.000 description 2
- 238000002512 chemotherapy Methods 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 230000006378 damage Effects 0.000 description 2
- 239000004053 dental implant Substances 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 239000012897 dilution medium Substances 0.000 description 2
- 230000002255 enzymatic effect Effects 0.000 description 2
- 201000005562 gingival recession Diseases 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000002906 microbiologic effect Effects 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 238000010172 mouse model Methods 0.000 description 2
- 210000004400 mucous membrane Anatomy 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- 150000007524 organic acids Chemical class 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 230000001717 pathogenic effect Effects 0.000 description 2
- 235000019319 peptone Nutrition 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 238000001959 radiotherapy Methods 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 238000003860 storage Methods 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 235000000346 sugar Nutrition 0.000 description 2
- QAXBVGVYDCAVLV-UHFFFAOYSA-N tiletamine Chemical compound C=1C=CSC=1C1(NCC)CCCCC1=O QAXBVGVYDCAVLV-UHFFFAOYSA-N 0.000 description 2
- 229940078499 tricalcium phosphate Drugs 0.000 description 2
- 229910000391 tricalcium phosphate Inorganic materials 0.000 description 2
- 239000003981 vehicle Substances 0.000 description 2
- 229910002012 Aerosil® Inorganic materials 0.000 description 1
- 241001116389 Aloe Species 0.000 description 1
- 208000002679 Alveolar Bone Loss Diseases 0.000 description 1
- 206010002091 Anaesthesia Diseases 0.000 description 1
- 108010062877 Bacteriocins Proteins 0.000 description 1
- 241000901050 Bifidobacterium animalis subsp. lactis Species 0.000 description 1
- 206010006326 Breath odour Diseases 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 241000207199 Citrus Species 0.000 description 1
- 235000005979 Citrus limon Nutrition 0.000 description 1
- 244000131522 Citrus pyriformis Species 0.000 description 1
- 208000027244 Dysbiosis Diseases 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 241000192125 Firmicutes Species 0.000 description 1
- 241000555712 Forsythia Species 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- 241000605986 Fusobacterium nucleatum Species 0.000 description 1
- 102000009338 Gastric Mucins Human genes 0.000 description 1
- 108010009066 Gastric Mucins Proteins 0.000 description 1
- 208000003433 Gingival Pocket Diseases 0.000 description 1
- 206010018276 Gingival bleeding Diseases 0.000 description 1
- 206010018785 Gingival infections Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 208000032139 Halitosis Diseases 0.000 description 1
- 206010022678 Intestinal infections Diseases 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000186610 Lactobacillus sp. Species 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N Lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- PQMWYJDJHJQZDE-UHFFFAOYSA-M Methantheline bromide Chemical compound [Br-].C1=CC=C2C(C(=O)OCC[N+](C)(CC)CC)C3=CC=CC=C3OC2=C1 PQMWYJDJHJQZDE-UHFFFAOYSA-M 0.000 description 1
- 206010048685 Oral infection Diseases 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 206010057249 Phagocytosis Diseases 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 206010035664 Pneumonia Diseases 0.000 description 1
- 241001135209 Prevotella denticola Species 0.000 description 1
- 241000293869 Salmonella enterica subsp. enterica serovar Typhimurium Species 0.000 description 1
- XUIMIQQOPSSXEZ-UHFFFAOYSA-N Silicon Chemical compound [Si] XUIMIQQOPSSXEZ-UHFFFAOYSA-N 0.000 description 1
- 229910000831 Steel Inorganic materials 0.000 description 1
- 241000888288 Streptococcus salivarius K12 Species 0.000 description 1
- 241000762063 Streptococcus salivarius M18 Species 0.000 description 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
- 206010042674 Swelling Diseases 0.000 description 1
- 230000024932 T cell mediated immunity Effects 0.000 description 1
- 241001135235 Tannerella forsythia Species 0.000 description 1
- 208000008312 Tooth Loss Diseases 0.000 description 1
- 241000589892 Treponema denticola Species 0.000 description 1
- 244000078912 Trichosanthes cucumerina Species 0.000 description 1
- 235000008322 Trichosanthes cucumerina Nutrition 0.000 description 1
- 208000025865 Ulcer Diseases 0.000 description 1
- 240000000851 Vaccinium corymbosum Species 0.000 description 1
- 235000003095 Vaccinium corymbosum Nutrition 0.000 description 1
- 235000017537 Vaccinium myrtillus Nutrition 0.000 description 1
- 208000036142 Viral infection Diseases 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 206010000269 abscess Diseases 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 239000013543 active substance Substances 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000002411 adverse Effects 0.000 description 1
- 235000011399 aloe vera Nutrition 0.000 description 1
- 230000004075 alteration Effects 0.000 description 1
- 230000037005 anaesthesia Effects 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 230000000844 anti-bacterial effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 239000003899 bactericide agent Substances 0.000 description 1
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 1
- 239000012620 biological material Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000021014 blueberries Nutrition 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 229910052794 bromium Inorganic materials 0.000 description 1
- 210000005178 buccal mucosa Anatomy 0.000 description 1
- 239000006172 buffering agent Substances 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 235000014633 carbohydrates Nutrition 0.000 description 1
- 230000005800 cardiovascular problem Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000001055 chewing effect Effects 0.000 description 1
- 239000000460 chlorine Substances 0.000 description 1
- 229910052801 chlorine Inorganic materials 0.000 description 1
- 208000001277 chronic periodontitis Diseases 0.000 description 1
- 235000020971 citrus fruits Nutrition 0.000 description 1
- FDJOLVPMNUYSCM-WZHZPDAFSA-L cobalt(3+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+3].N#[C-].N([C@@H]([C@]1(C)[N-]\C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C(\C)/C1=N/C([C@H]([C@@]1(CC(N)=O)C)CCC(N)=O)=C\C1=N\C([C@H](C1(C)C)CCC(N)=O)=C/1C)[C@@H]2CC(N)=O)=C\1[C@]2(C)CCC(=O)NC[C@@H](C)OP([O-])(=O)O[C@H]1[C@@H](O)[C@@H](N2C3=CC(C)=C(C)C=C3N=C2)O[C@@H]1CO FDJOLVPMNUYSCM-WZHZPDAFSA-L 0.000 description 1
- 210000002808 connective tissue Anatomy 0.000 description 1
- 231100000433 cytotoxic Toxicity 0.000 description 1
- 230000001472 cytotoxic effect Effects 0.000 description 1
- 235000013365 dairy product Nutrition 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 230000007123 defense Effects 0.000 description 1
- 238000005115 demineralization Methods 0.000 description 1
- 230000002328 demineralizing effect Effects 0.000 description 1
- 210000004268 dentin Anatomy 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000676 disease causative agent Toxicity 0.000 description 1
- 229910000397 disodium phosphate Inorganic materials 0.000 description 1
- 235000019800 disodium phosphate Nutrition 0.000 description 1
- 239000006185 dispersion Substances 0.000 description 1
- 238000009826 distribution Methods 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000007140 dysbiosis Effects 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 206010016256 fatigue Diseases 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 229940068517 fruit extracts Drugs 0.000 description 1
- 239000003349 gelling agent Substances 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 125000003976 glyceryl group Chemical group [H]C([*])([H])C(O[H])([H])C(O[H])([H])[H] 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 208000011759 gum bleeding Diseases 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000028996 humoral immune response Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000008076 immune mechanism Effects 0.000 description 1
- 229960003444 immunosuppressant agent Drugs 0.000 description 1
- 239000003018 immunosuppressive agent Substances 0.000 description 1
- 239000007943 implant Substances 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 210000000936 intestine Anatomy 0.000 description 1
- PNDPGZBMCMUPRI-UHFFFAOYSA-N iodine Chemical compound II PNDPGZBMCMUPRI-UHFFFAOYSA-N 0.000 description 1
- 238000002955 isolation Methods 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 229940001882 lactobacillus reuteri Drugs 0.000 description 1
- 230000002045 lasting effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 210000003041 ligament Anatomy 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000037353 metabolic pathway Effects 0.000 description 1
- 230000004060 metabolic process Effects 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- 150000002739 metals Chemical class 0.000 description 1
- MYWUZJCMWCOHBA-VIFPVBQESA-N methamphetamine Chemical compound CN[C@@H](C)CC1=CC=CC=C1 MYWUZJCMWCOHBA-VIFPVBQESA-N 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 238000012543 microbiological analysis Methods 0.000 description 1
- 210000002200 mouth mucosa Anatomy 0.000 description 1
- 210000004877 mucosa Anatomy 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 238000005457 optimization Methods 0.000 description 1
- 229940100692 oral suspension Drugs 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 230000036407 pain Effects 0.000 description 1
- 239000002245 particle Substances 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 230000003239 periodontal effect Effects 0.000 description 1
- 210000004261 periodontium Anatomy 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 230000008782 phagocytosis Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 239000000047 product Substances 0.000 description 1
- 230000000770 proinflammatory effect Effects 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 235000018102 proteins Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000006254 rheological additive Substances 0.000 description 1
- 239000006152 selective media Substances 0.000 description 1
- 239000008299 semisolid dosage form Substances 0.000 description 1
- 229910052710 silicon Inorganic materials 0.000 description 1
- 239000010703 silicon Substances 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- 239000001488 sodium phosphate Substances 0.000 description 1
- 239000010959 steel Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 239000011593 sulfur Substances 0.000 description 1
- 229910052717 sulfur Inorganic materials 0.000 description 1
- 230000004083 survival effect Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 230000008961 swelling Effects 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 239000007916 tablet composition Substances 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 229960004523 tiletamine Drugs 0.000 description 1
- 230000003867 tiredness Effects 0.000 description 1
- 208000016255 tiredness Diseases 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 235000019731 tricalcium phosphate Nutrition 0.000 description 1
- LADGBHLMCUINGV-UHFFFAOYSA-N tricaprin Chemical compound CCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCC)COC(=O)CCCCCCCCC LADGBHLMCUINGV-UHFFFAOYSA-N 0.000 description 1
- 230000036269 ulceration Effects 0.000 description 1
- 238000009827 uniform distribution Methods 0.000 description 1
- 230000009385 viral infection Effects 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 239000000341 volatile oil Substances 0.000 description 1
- 238000003260 vortexing Methods 0.000 description 1
- 230000036642 wellbeing Effects 0.000 description 1
- BPICBUSOMSTKRF-UHFFFAOYSA-N xylazine Chemical compound CC1=CC=CC(C)=C1NC1=NCCCS1 BPICBUSOMSTKRF-UHFFFAOYSA-N 0.000 description 1
- 229960001600 xylazine Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
- A61K9/0063—Periodont
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/745—Bifidobacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
- A61K35/741—Probiotics
- A61K35/744—Lactic acid bacteria, e.g. enterococci, pediococci, lactococci, streptococci or leuconostocs
- A61K35/747—Lactobacilli, e.g. L. acidophilus or L. brevis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
- A61K47/38—Cellulose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
Definitions
- the present invention relates to mucoadhesive gels comprising probiotics, to the process for their preparation and to their use for the prevention and treatment of pathologies of the oral cavity.
- Dental plaque consists of a microbial biofilm and is the main component of the bacterial ecosystem (microbiota) present in the oral cavity.
- microbiota bacterial ecosystem
- the oral microbiota constitutes a defense system of the oral cavity, preventing the colonization of the mouth by pathogenic bacteria.
- An imbalance in the composition of the dental biofilm can give rise to the appearance of dental caries and gingival and periodontal infections/inflammations [Rinkee Mohanty, et al. J Family Med Prim Care. 2019, 8: 3480- 3486],
- endogenous bacteria mainly Streptococci mutans present in the biofilm, produce weak organic acids as a by-product of the metabolism of fermentable carbohydrates, with a decrease in pH and consequent teeth tissues demineralization [Selwiz R.H.
- Periodontal diseases are largely due to specific infections caused by anaerobic Gram-negative bacteria which, if neglected, lead to damage of the soft connective tissue of the gum and, subsequently, to the loss of the underlying alveolar bone and ligament supporting the teeth.
- Porphyromonas gingivalis mainly involved in the development and progression of periodontitis there are Porphyromonas gingivalis, Treponema denticola, Prevotella denticola, Tannerella forsythia, Aggregatibacter actynomycetecomitans and Fusobacterium nucleatum, which together constitute the red complex, a group of bacteria classified together based on their association with severe forms of periodontal disease.
- probiotic means "alive microorganisms that, administered in adequate amounts, provide benefit to the health of the host'.
- the FAO/WHO document giving this definition refers to non-pathogenic microorganisms, lactobacilli and bifidobacteria, present or added to food, which are able to exert beneficial effects to the body.
- Lactobacilli are Gram-positive bacteria, they obtain the energy necessary for their survival thanks to a fermentation process of hexose sugars (for example, glucose, mannose, fructose, etc.) by producing lactic acid and ethanol. Other bacteria producing lactic acid from sugars, albeit via a different metabolic pathway, are bifidobacteria. Lactobacilli and bifidobacteria belong to the group of bacteria defined as "probiotics", which carry out a series of beneficial actions, especially, but not only, in the intestine of Mammals and in particular in Humans.
- probiotics secrete several antimicrobial substances, such as enzymes, organic acids, hydrogen peroxide and bacteriocins, and compete with buccal pathogens for mucosal adhesion sites [Meurman J.H. et al. Eur J Oral Sci 2005; 113: 188-1962],
- lactic acid bacteria and bifidobacteria represents an alternative and promising therapeutic opportunity, as well as being an effective method for maintaining correct dental and oral cavity health.
- Probiotic lactobacilli and bifidobacteria can compromise the viability of pathogenic microorganisms through the modulation of the pH and/or the redox potential of the environment in which they live, by stimulating non-specific immune mechanisms and modulating the humoral and cellular immune response [Marco M.L. et al., Curr. Opin. Biotech. 2006, 17: 204-210],
- Lactobacillus brevis ATCC 4006 may have beneficial effects in the treatment of some oral diseases.
- This probiotic is currently marketed in an orodispersible tablet formulation, under the name Inersan®.
- Inersan® an anti-inflammatory effect determined by the composition was found.
- Piyush Shah et al. J. Clin. Diagn. Res., 2013, 7: 595-600 describes a clinical study wherein the effect of the probiotic Inersan® administered to patients with periodontitis is compared with the combination of the probiotic with the antibiotic doxycycline, and with the effect determined by the administration of the antibiotic alone.
- the study has shown that the probiotic composition based on lactobacilli was able to perform a favorable action on gingival inflammation and in preventing the appearance of caries, without the need to take doxycycline and therefore eliminating the problems associated with drug resistance towards antibiotics.
- Clin Oral Investig., 2015; 19: 77-83 discloses the use of a tablet formulation comprising Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12, with a 4-week treatment in healthy patients.
- the study has shown that shortterm consumption of L. rhamnosus LGG and B. animalis BB-12 is sufficient to determine a decrease in the amount of bacterial plaque associated with gingival inflammation.
- the strain Lactobacillus rhamnosus SP1 (DSM 21690) was used in a study aimed to evaluate the effect of administering this probiotic on improving dental health in a group of 205 preschool children in Chile.
- the L. rhamnosus SP1 strain is given in freeze-dried form (1 .5 billion of alive lactic ferments) as a food supplement in 150 ml of milk in the afternoon snack consumed at school.
- the nutraceutical product Kijimea® K53 comprising probiotic strains Lactobacillus rhamnosus SP1 (DSM 21690) and Lactobacillus helveticus SP27 (DSM 29575), together with other 51 strains of probiotic bacteria, is indicated for use in states of tiredness and fatigue.
- the composition also includes vitamin B12 and biotin.
- Vuotto et al. (Oral Diseases, 2013; 20: 668-674) describes the use of Lactobacillus brevis to prevent the formation of the buccal biofilm caused by Prevotella melaninogenica, one of the causative agents of periodontitis.
- WO 2018/169296 discloses mucoadhesive buccal films comprising probiotic bacteria (e.g. Lactobacillus brevis).
- the films contain gelling agents and are made by drying of highly viscous solutions.
- Mucoadhesive films for the release of alive lactobacilli represent a suitable dosage form for the treatment of oral cavity disorders but require long production times with consequent loss of vitality during the preparation process and during the storage.
- Patent application CN 107865891 describes probiotic compositions, in form of gel, useful for inhibiting the growth of periodontal pathogens and for preventing and treating periodontitis.
- probiotics include Lactobacillus acidophilus (10-30%), Streptococcus salivarius M18 (10-50%) and Streptococcus salivarius K12 (20-80%) bacteria, overall in amount from 10 7 to 10 10 CFU/ml, and pharmaceutically acceptable vehicles or excipients, wherein the bacterial suspension is mixed with a matrix comprising 1 -10% modified cellulose-based polymeric gel, in oily carrier, to which hydroxypropyl methylcellulose as bioadhesive material is added, and a silicon-based rheological modifier.
- the document shows composition stability data for up to six months of storage.
- compositions that are able to keep probiotics alive and to release them in the mouth in a controlled manner. It is also important that the composition remains adhered to the buccal mucosa and is also accepted by the subjects.
- Semi-solid dosage forms such as mucoadhesive oral gels have the advantage of ensuring a more intimate contact and an easier and faster dispersion of the active ingredients, the probiotic, its enzymes and pharmacologically active substances, through the oral mucosa.
- a composition in the form of a mucoadhesive gel, comprising probiotics in amounts higher than 1x10 7 CFU/g which are released in a time longer than six hours, has surprisingly been found, and it is the object of the present invention.
- the gel is stable at room temperature and is characterized by an extreme ease of administration.
- the object of the invention is a mucoadhesive gel composition
- a probiotic in an amount from 1x10 7 to 1x10 15 CFU/g; from 50 to 85% (w/w), with respect to the weight of the final composition, of a dispersing agent selected from the group consisting of: esters of fatty acid (C4-C30) with glycols, lecithins, non-ionic waxes, phospholipids, polaxamers, polyoxy alkyl esters, castor oil derivatives, polyoxyethylene esters of sorbitan and fatty acids, polyglycerides, povidone, stearic acid, esters of stearic acid and glycerin, sorbitan esters, starch, hydroxy stearate, and mixture thereof; from 5 to 20% (w/w), with respect to the weight of the final composition, of a bioadhesive agent selected from the group consisting of: glyceryl monooleate, hydroxypropylmethyl
- the probiotics according to the present invention are preferably selected from the group consisting of: lactobacilli selected from the group consisting of: Lactobacilli salivarus, Lactobacilli brevis, Lactobacilli helveticus, Lactobacilli paracasei, Lactobacilli rhamnosus, Lactobacilli animalis, Lactobacilli reuteri, Lactobacilli plantarum, Lactobacilli acidophilus, Lactobacilli belbrueckir, Bifidobacteria selected from the group consisting of: Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium brevis, Streptococcus thermophilus, and mixtures thereof.
- lactobacilli selected from the group consisting of: Lactobacilli salivarus, Lactobacilli brevis, Lactobacilli helveticus, Lactobacilli paracasei, Lactobacilli rhamnos
- a second aspect of the present invention is to provide a process for the preparation of a mucoadhesive gel composition according to claim 1 comprising the following steps: a. providing said dispersing agent in an amount of 50-85 % (w/w) and adding said viscosifying mixture in an amount of 10-30% (w/w), at a temperature between 50 and 80 °C; b. adding said bioadhesive agent in an amount of 5 to 20% (w/w); c. cooling down to room temperature; d. adding under stirring said probiotics in an amount from 1x10 7 to 1x10 15 CFU/g; and e. aliquoting in a chosen dosage.
- a third object of the invention is the use of the mucoadhesive composition for the prevention and treatment of disorders, pathologies and inflammations of the oral cavity, gingivitis, peri- implantitis, periodontitis, stomatitis and caries.
- Figure 2 Release of probiotics (L. rhamnosus SP1 DSM 21690 and L. helveticus SP27 DSM 29575) included in GEL 6A formulation (AL0006).
- Figure 3 Release of probiotics (L rhamnosus SP1 DSM 21690, L. helveticus SP27 DSM 29575 and L. paracasei LGM S-26420) included in the GEL 6D formulation (AL0007).
- probiotics L rhamnosus SP1 DSM 21690, L. helveticus SP27 DSM 29575 and L. paracasei LGM S-26420
- Figure 4 Graph showing the variation over time in the body weight of mice over the 28-day study period.
- Figure 5 Graph showing the variation over time in mm of the maxillary alveolar bone in animals over the 28-day treatment period.
- the present invention relates to a mucoadhesive gel comprising at least one probiotic for the treatment and/or prevention of disorders, pathologies of the oral cavity.
- the mucoadhesive gel is characterized by releasing the probiotics included in the formulation in a time longer than six hours.
- the mucoadhesive gel comprises a dispersing agent in an amount from 50 to 85% (w/w), a viscosifying mixture in an amount from 10 to 30% (w/w), and a bioadhesive agent in an amount from 5 to 20% (w/w), with respect to the total weight of the composition.
- the gel may further comprise pharmaceutical excipients such as sweetening, preserving and flavoring agents.
- the dispersing agent is selected from the group consisting of: esters of fatty acid (C4-C30) with glycols, lecithins, non-ionic waxes, phospholipids, polyxamers, polyoxy alkyl esters, castor oil derivatives, polyoxyethylene esters of sorbitan and fatty acids, polyglycerides, povidone, stearic acid, esters of stearic acid and glycerin, sorbitan esters, starch, hydroxy stearate, and mixture thereof.
- the bioadhesive agent is selected from the group consisting of: glyceryl monooleate, hydroxypropylmethyl cellulose with viscosity from 750 to 1400 mPa sec in a 2% (w/w) aqueous solution, polycarbophil, polyethylene oxide, carbomers, dextrins, glucans, and mixture thereof;
- the viscosifying mixture according to the invention comprises: from 60.0 to 90.0% (w/w), with respect to the weight of said mixture of a viscosifying agent selected from the group consisting of: glyceryl behenate, agar, bentonite, xanthan gum, xyloglucans, hyaluronic acid esters with molecular weight higher than 300KDa, linseed, acacia gum, arabic gum, alginic acid and its esters, corn starch, colloidal bentonite, lanolin, waxes, beeswax, palmitic acid esters cellulose, ethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, cellulose, myristilic acid, polyvinyl acetate, povidone, alginate, carrageenan, cetostearyl alcohol, chitosan, gelatin, glycerin, type 1 vegetable oil, silica, sucrose, hydroxypropyl methylcellulose
- the preferred viscosifying agent is a mixture of viscosifying agents consisting of ethyl cellulose, glyceryl behenate, hydroxypropyl methylcellulose with a viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution.
- the term dispersing agent refers to a compound or a compounds mixture that, added to a composition improving the separation of particles and prevents settling or clumping.
- bioadhesive or mucoadhesive agent refers to natural materials that act as adhesives, in particular refers to a material designed to adhere to biological tissue.
- the term viscosifying agent refers to a substance that can increase the viscosity of a liquid without substantially changing its other properties.
- the preferred heteroatoms are nitrogen, oxygen, sulfur, phosphorus, chlorine, bromine, and iodine, as well as the metals lithium and magnesium.
- the substituted silica is dimethyl silylated silica.
- the viscosifying agent comprises a said substituted silica in an amount from 2.5 % to 5.0 % (w/w), with respect to the weight of the final composition.
- said dispersing agent is in an amount from 60 to 75% (w/w), with respect to the weight of the final composition; said bioadhesive agent is in amount from 5 to 10% (w/w), with respect to the weight of the final composition; said viscosifying mixture is in an amount from 20 to 30% (w/w), with respect to the weight of the final composition.
- the mucoadhesive gel composition comprises probiotics in an amount from 1x10 7 to 1x10 15 CFU/g, a dispersing agent consisting of a mixture of esters of fatty acids (C4-C30) with glycols, in an amount from 60 to 75% (w/w) with respect to the total weight of the composition, a viscosifying mixture consisting of ethyl cellulose, glyceryl behenate, substituted silica and hydroxypropyl methylcellulose with a viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution respectively in a weight ratio 1 :0.5: 1 to 1 :1 :5, a bioadhesive agent consisting of hydroxypropyl methylcellulose with viscosity from 750 to 1400 mPa sec in a 2% (w/w) aqueous solution in an amount from 5 to 10% (w/w), relative to the total weight of
- the mucoadhesive gel composition comprises the viscosifying mixture consisting of a mixture of ethyl cellulose, glyceryl behenate, substituted silica and hydroxypropyl methylcellulose with a viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution (Benecell K4M), in a weight ratio from 1 : 0.5: 1 : 1 to 1 : 1 : 5: 10.
- the mucoadhesive gel composition is characterized by comprising a mixture of high viscosity hydroxypropyl methylcellulose, in which a hydroxypropyl methylcellulose characterized by producing a viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution and a hydroxypropyl methylcellulose characterized by producing a viscosity from 750 to 1400 mPa sec in a 2% (w/w) aqueous solution, which are respectively in a weight ratio from 0.5: 1 .5 to 1 :5.
- the mucoadhesive gel composition comprising esters of caprylic and/or capric acid with propylene glycol in an amount from 50.0 to 80.5% (w/w), ethyl cellulose 5.0-10.0% (w/w), glyceryl behenate 2.5-10.0% (w/w), dimethyl silylated silica 2.5-5.0% (w/w), hydroxypropylmethyl cellulose with a viscosity from 750 to 1400 mPa sec in a 2% (w/w) aqueous solution, in an amount from 5 to 20% (w/w), and hydroxypropylmethyl cellulose with viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution, in an amount from 5.0 to 10.0% (w/w), with respect to the final composition.
- the mucoadhesive gel composition according to the present invention can also comprise pharmaceutically acceptable excipients such as preserving agents, buffering agents, flavoring agents.
- Flavoring agents are selected from the group comprising natural plant, citrus and fruit extracts.
- the mucoadhesive gel composition is characterized by being lipophilic and is homogeneous without separation of the oily phase from the gel phase.
- the mucoadhesive gel composition according to the invention is characterized by a viscosity measurement between W and 40 mPa sec when a shear stress from 1 to 10 s -1 is applied.
- the viscosity of the formulation is between 14 and 38 mPa sec when a shear stress from 1 to 10 s _1 is applied.
- composition of the mucoadhesive gel is characterized by an adhesion to a mucin layer by more than 70% compared to an aqueous solution.
- the mucoadhesive composition offers the advantage of releasing probiotics into the oral cavity in a controlled manner, increasing the therapeutic efficacy with less frequency of administration.
- the composition in gel form has the advantage to be easily administered one or more time in a day and well accepted by the subject.
- the mucoadhesive gel composition according to the present invention does not contain water or is substantially free of water.
- the gel composition includes one or more probiotics, belonging to the lactobacilli and/or bifidobacteria species selected from the group comprising: Lactobacilli salivarus, Lactobacilli brevis, Lactobacilli helveticus, Lactobacilli paracasei, Lactobacilli rhamnosus, Lactobacilli animalis, Lactobacilli reuteri, and bifidobacteria, as for example, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium brevis and/or their mixtures.
- probiotics belonging to the lactobacilli and/or bifidobacteria species selected from the group comprising: Lactobacilli salivarus, Lactobacilli brevis, Lactobacilli helveticus, Lactobacilli paracasei, Lactobacilli rhamnosus, Lactobacilli animalis, Lactobacilli
- the mucoadhesive gel composition preferably comprises the probiotics selected from the group comprising: Lactobacillus rhamnosus (DSM 21690), Lactobacillus helveticus (DSM 29575), Lactobacillus paracasei (LGM S-26420), and/or their mixtures, in amounts of 1x10 9 -1x10 17 (CFU/100g).
- the probiotics selected from the group comprising: Lactobacillus rhamnosus (DSM 21690), Lactobacillus helveticus (DSM 29575), Lactobacillus paracasei (LGM S-26420), and/or their mixtures, in amounts of 1x10 9 -1x10 17 (CFU/100g).
- Lactobacillus rhamnosus (DSM 21690), Lactobacillus helveticus (DSM 29575) and Lactobacillus paracasei (LGM S-26420) in amounts of 1x10 9 -1x10 17 (CFU/100g) and/or their mixtures are released in a time from 10 minutes to 6 hours.
- the unitary composition is reported in Table 1 :
- the mucoadhesive gel composition according to the invention is characterized by the ability to release probiotic microorganisms in a controlled manner, in a percentage greater than 70%, in a time from ten minutes to six hours, in which the probiotics maintain their vitality.
- the gel has a good adhesion to several types of materials, both of non-specific nature, such as filter paper, and polycrystalline bioceramic, a dentin mimicking material.
- the gel allows the release of probiotics from the gel into the mucous membrane of the oral cavity and into the dental biofilm.
- composition is characterized by releasing the probiotics in a solution (artificial saliva), in a time from ten minutes to two hours, in which a percentage greater than 60% of the probiotics are released after 2 hours, and a percentage of the 75% after 5 hours.
- the mucoadhesive gel composition releases a percentage of L. rhamnosus SP1 (DSM 21690) and L. helveticus SP27 (DSM 29575) equal to 62%, and in a percentage from 60% to 70% after two hours and adheres to the surface of microcrystalline bioceramic, the release percentage remains practically constant from 50% to 70% from ten minutes to six hours.
- the percentage of probiotics released from the mucoadhesive gel containing L. rhamnosus SP1 (DSM 21690), L. helveticus SP27 (DSM 29575) and L. paracasei CBA-L87 (LGM S- 26420) and adhered to the surface ranges from 50 to 70% after two hours, and it rises up to 80% after 8 hours. Therefore, the bacteria released from the gel preparation maintain their ability to adhere to the surface and to maintain their vitality for a very long time and such as to allow them to exert their beneficial effect at the application site, up to eight hours after administration, thus favoring a greater distribution and release of probiotics even in the gingival pockets.
- the mucoadhesive gel composition includes probiotics selected in the group comprising L. rhamnosus SP1 (DSM 21690), L. helveticus SP27 (DSM 29575) and L. paracasei CBA-L87 (LGM S-26420) and their mixtures, which inhibit the growth of pathogenic bacteria responsible for periodontal infections in the oral microbiome.
- probiotics selected in the group comprising L. rhamnosus SP1 (DSM 21690), L. helveticus SP27 (DSM 29575) and L. paracasei CBA-L87 (LGM S-26420) and their mixtures, which inhibit the growth of pathogenic bacteria responsible for periodontal infections in the oral microbiome.
- the dispersing agent is an ester of capric and/or caprylic acid with propylene glycol, in an amount of 50.0 to 80.5% (w/w);
- the viscosifying mixture is ethyl cellulose, in an amount from 5.0 to 10.0% (w/w), glyceryl behenate in an amount from 2.5 to 10.0% (w/w) hydroxypropyl methylcellulose with viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution from 5.0 to 20.0% (w/w) and dimethyl silylated silica in an amount from 2.0 to 5.0% (w/w);
- the bioadhesive agent is hydroxypropyl methylcellulose with viscosity from 750 to 1400 mPa- sec in a 2% (w/w) aqueous solution in an amount from 5.0 to 20.0% (w/w); and the probiotics are selected from the group consisting of:
- the mucoadhesive gel composition according to the invention is dispensed in tubes of 5, 10, 15, 50 grams and stored at room temperature.
- Another object of the present invention is a medical device comprising the mucoadhesive gel comprising probiotics.
- the mucoadhesive gel composition according to the invention is stable for at least 6 months, at room temperature, period wherein the viability of the probiotic strains remains unaltered.
- the mucoadhesive gel composition according to the invention is useful for the treatment and/or prevention of oral diseases, in the prevention of periodontitis, gingivitis, stomatitis and caries.
- the effectiveness of the formulation according to the invention has been confirmed in a mouse model in which inflammation was induced by ligating the teeth.
- the mucoadhesive gel comprising probiotics L. rhamnosus SP1 (DSM 21690), L. helveticus SP27 (DSM 29575) and L. paracasei CBA-L87 (LGM S-26420) was found to be significantly effective compared to the gel without probiotics.
- the composition comprising L. rhamnosus SP1 (DSM 21690) and L. helveticus SP27 (DSM 29575) is effective in preventing tooth loss in a percentage from 80 to 90% compared to the gel without probiotics in which the percentage ranges from 20 to 40 %.
- the mucoadhesive gel composition according to the invention is useful for recovering alveolar bone loss which was particularly sensitive in the group treated with the mucoadhesive gel comprising L. rhamnosus SP1 (DSM 21690) and L. helveticus SP27 (DSM 29575), as shown in Figure 5.
- the mucoadhesive gel composition according to the invention useful for preventing problems in the oral cavity, such as periodontitis (pyorrhea), halitosis, gingival recession, gum bleeding, abscess and swelling of the gums, pain and difficulty while chewing.
- the composition is also useful for preventing/treating peri-implantitis, or the bacterial infection that develops around dental implants.
- the mucoadhesive gel composition according to the invention can be used in combination with antibiotics, chemotherapy, radiotherapy, immunosuppressants.
- the mucoadhesive gel composition according to the invention can be applied to the gums one to five times a day; it is well tolerated and has no toxic or adverse effects either on the mucosa or at a systemic level.
- Preparations of 100 grams of six gels were obtained by placing in a mixer in the following order: ethyl cellulose and ester of capric and caprylic acid with propylene glycol at a temperature of 85°C. The mixture was kept stirring until homogeneous, then brought to room temperature.
- Glyceryl beetate dimethyl silylated silica (Aerosil® R972), hydroxy-propylmethylcellulose (Benecell K4M) and (Benecell K100M) were added to the six homogeneous mixtures and the final mixtures were kept stirred until homogeneous mixtures were obtained.
- the unitary compositions are reported in Table 5.
- Gel compositions 1 -6 were placed in glass tubes and after 24 hours centrifuged at 3000 rpm for 15 min and their appearance was evaluated: Gel 1 : the oily phase is separated from the gel phase by approximately 50%
- Gel 2 the oily phase is separated from the gel phase by about 20%
- Gel 5 the oily phase is separated from the gel by about 1 %
- Gel 6 the gel is homogeneous without separation of the oily phase from the gel phase.
- Gel 6 Formulation (AL0005) was chosen for preparations of gel containing probiotics.
- the lyophilized bacteria of one of the probiotic strains were added to an amount of gel equal to 10 grams of GEL 6 obtained as shown in example 1 : B. animalis subsp. lactis BCL01 (DSM 17741 ), Lactobacillus rhamnosus SP 1 (DSM 21690) Lactobacillus reuteri LR92 (DSM 26866), Lactobacillus brevis SP48 (DSM 16806), Lactobacillus helveticus SP27 (DSM 29575), all registered with the Deutsche Organism Braunschweig, Germany, or the lyophilized bacteria of the Lactobacillus paracasei strain (LGM S-26420), deposited at the Belgian Coordinated Collection of Microorganism - BCCM/LMG Bacteria Collection, Laboratory for Microbiology, Ghent University.
- the amount of bacteria released from the formulation of GEL 6 loaded with bacteria of several strains in single form was evaluated both in physiological solution and in an artificial saliva solution at time intervals of 30 minutes, 2 hours, 5 hours and 8 hours.
- the initial and residual bacterial load in the gels at various time intervals, and in parallel the amount of bacteria released in the two types of solution were determined [Pantanella F. et al. Journal of Microbiological Meth., 2008, 75: 478-484],
- 400 mg of each probiotic gel preparation were divided into 10 tubes, each containing 40 mg of gel, and divided into two series of 5 tubes each.
- Example 4 PREPARATION OF THE GEL COMPOSITION CONTAINING MIXTURES OF PROBIOTIC STRAINS Based on the results obtained with the probiotic gel preparations containing only one probiotic strain, the gel formulations containing the probiotic strains L. paracasei (LGM S- 26420), L. rhamnosus SP1 (DSM 21690) and L. helveticus SP27 (DSM 29575) in association with each other as indicated in Table 9 were prepared. The preparations were carried out on a 10 grams scale by adding the bacteria in lyophilized form to the preparation 6 of Example 1 . In Table 9 the starting bacterial load of the single strains in lyophilized form and of the probiotic mixtures before being added to GEL 6 is indicated by CFU count and the BioTimer method.
- Example 2 The amount of bacteria released from GEL 6/l-VI compositions (Example 2) was evaluated in physiological solution at time intervals of 30 min, 2 hours, 5 hours and 8 hours as described in Example 4. The results obtained for the four compositions are reported in Table 10.
- Table 11 shows the viscosity values with shear stress equal to 10 s’ 1 .
- the in vitro determination of the mucoadhesiveness of the GEL 6 formulation, prepared according to example 1 was carried out using the inert inclined plane method in the presence of a mucin biofilm, compared to an aqueous solution.
- the test was carried out by sliding the sample on an inert support (steel) covered with a layer of 8% porcine gastric mucin.
- the adhesion on the mucin layer was evaluated in relation to the adhesion of the same sample on the inclined inert support not covered with mucin.
- the actual mucoadhesion is determined by the delay in the flow of the sample and in the detachment from the plane caused by the presence of mucin.
- a sample In order to be considered mucoadhesive, a sample have to demonstrate an adhesion compared to the control without mucin significantly higher than that one demonstrated by water, which interacts with the protein for hygroscopic absorption only.
- Caprylic/capric triglyceride and ethyl cellulose were placed in a mixer, the temperature was brought to 85-90° C until a homogeneous mixture was obtained.
- Glyceryl behenate, dimethyl silylated silica and the mixture of hydroxypropyl methylcellulose, (BenecellTM K4M and BenecellTM K100M) were added, and the homogeneous mass was brought to room temperature. Subsequently, blueberry and aloe extracts were added. The mixture was kept under stirring until a homogeneous and finely dispersed gel was obtained. Finally, lemon essential oil and freeze-dried probiotics are added.
- the amount of bacteria released from the gel compositions Gel 6A and 6D was evaluated in physiological solution at time intervals of 30 min, 2 hours, 5 hours and 8 hours as described in example 3.
- the results obtained for the Gel 6A formulation, including the probiotic strains L. rhamnosus and L. helveticus are shown in Table 14 and the results obtained for the GEL 6D formulation, including the probiotic strains L. rhamnosus and L. helveticus and L. paracasei are shown in Table 15.
- MRD Enzymatic digest of casein or peptone 1 g/L, sodium chloride 8.5 g/L
- SS artificial saliva
- the obtained data demonstrate that the bacteria of both associations of probiotics released from the gel maintain their viability up to 5 hours under the conditions that simulate the environment of the oral cavity suspended in the saliva solution at a level slightly lower than those considered to be the optimal conditions for the recovery of the growth of a microorganism after stressful conditions.
- Table 17 shows the obtained values expressed as Log CFU.
- the data show that the viability of probiotic strains released from the gel into a liquid vehicle, such as saliva, or released and adhered to a surface, albeit non-specific, remains substantially the same for a period of time up to 5 hours.
- the adhesive property of the bacteria released from the gels was determined using a [3- tricalcium phosphate ([3-TCP) disc model; 3D, Biotek, according to what is described in Honglue T et al. Biomaterials 2012, 33: 365-77.
- the discs were recovered and placed in a tube containing 9 ml of diluent (MRD or SS) depending on the one initially used.
- the bacteria adhered to each disk were removed by immersing the tubes in an ultrasonic bath followed by a short vortexing to evenly distribute the bacteria.
- serial decimal dilutions in same dilution medium (MRD or SS) were made and then they were plated on agar plates and incubated at 37 °C for 24 hours.
- the number of colonies grown on the plates was determined.
- P represents the percentage of adhesion of the mixture of bacteria to the [3-TCP disc 3D Biotek;
- [i represents the number of alive bacteria of the analyzed gel bound to the [3-TCP disc 3D Biotek expressed as a logarithmic value
- the efficacy of the gel composition comprising the probiotic strains L. paracasei (LGM S- 26420), L. rhamnosus SP1 (DSM 21690) and L. helveticus SP27 (DSM 29575) was determined in a mouse model of periodontitis induced by tooth ligation, as described by Abe T. and Hajishengallis G. in Optimization of the ligature-induced periodontitis model in mice, Journal of Immunological Methods 2013, 394, 49-54.
- mice Sixty C57BI/6 male mice, 9-10 weeks of age, were fed ad libitum with sterile food and water. On Day “0" the second maxillary molar tooth of the mice, mildly anesthetized, with a combination of Tiletamine and Xylazine (respectively, 25 mg/kg and 4 mg/kg), was tied with a 5-0 non-absorbable silk surgical suture, to induce inflammation of the periodontium. The mice were divided into four groups of 15 animals per group:
- mice of Groups 2-4 under anesthesia, were treated daily, 5 days a week, for three weeks, with the corresponding Gels. Gels were applied in the late afternoon. Subsequently, the animals were left without water for an hour, and then overnight fasted but with free access to water. Three animals per group were sacrificed on day “8", day “15” and day “22”. The remaining six animals were sacrificed on day “29”, after one week without Gel treatment.
- the loss of alveolar bone was evaluated with respect to the height of the bone in the unbound counterpart, furthermore, the amount of the gingival myeloperoxidase (MPO) enzyme was determined.
- myeloperoxidase acts as a bactericide by catalyzing the reaction of superoxide ions O2 produced by polymorph-nucleated leukocytes during phagocytosis, creating cytotoxic compounds which, in addition to favor the killing of bacteria and of other pathogens, can perform a significant pro-inflammatory action, and directly contribute to tissue damage in the body.
- the increase in its presence in saliva is an indicator of the presence of inflammatory phenomena of the mucous membranes or gingival tissue.
- a general clinical evaluation was also performed, and the body weight was checked and the loss of the bonded tooth was observed. The latter data is shown in Table 19.
- the stability of the two gels was evaluated by determining the bacterial load detected in the two formulations stored at room temperature for three and six months. The data are reported in Table 20.
- the number of bacterial counts of the two formulations does not undergo alteration and remains substantially unchanged after six months.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Biophysics (AREA)
- Inorganic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
Abstract
The present invention relates to mucoadhesive gels comprising probiotics, to the process for their preparation and to their use for the prevention and treatment of pathologies of the 5 oral cavity.
Description
BUCCAL MUCOADHESIVE GEL CONTAINING PROBIOTICS FOR USE IN THE PREVENTION AND TREATMENT OF PERIODONTAL DISEASES
OBJECT OF THE INVENTION
The present invention relates to mucoadhesive gels comprising probiotics, to the process for their preparation and to their use for the prevention and treatment of pathologies of the oral cavity.
STATE OF THE ART
Dental plaque consists of a microbial biofilm and is the main component of the bacterial ecosystem (microbiota) present in the oral cavity. There are many bacterial species that make up the microbiota of the oral cavity, in the order of several thousand, and it is estimated that about a thousand of these make up the biofilm colonizing the surface of the teeth.
The oral microbiota constitutes a defense system of the oral cavity, preventing the colonization of the mouth by pathogenic bacteria. An imbalance in the composition of the dental biofilm can give rise to the appearance of dental caries and gingival and periodontal infections/inflammations [Rinkee Mohanty, et al. J Family Med Prim Care. 2019, 8: 3480- 3486], For example, endogenous bacteria, mainly Streptococci mutans present in the biofilm, produce weak organic acids as a by-product of the metabolism of fermentable carbohydrates, with a decrease in pH and consequent teeth tissues demineralization [Selwiz R.H. et al., Lancet 2007; 369: 51 -59], Periodontal diseases (gingivitis and periodontitis) are largely due to specific infections caused by anaerobic Gram-negative bacteria which, if neglected, lead to damage of the soft connective tissue of the gum and, subsequently, to
the loss of the underlying alveolar bone and ligament supporting the teeth. Among the bacterial species mainly involved in the development and progression of periodontitis there are Porphyromonas gingivalis, Treponema denticola, Prevotella denticola, Tannerella forsythia, Aggregatibacter actynomycetecomitans and Fusobacterium nucleatum, which together constitute the red complex, a group of bacteria classified together based on their association with severe forms of periodontal disease.
According to the definition of the FAO and the WHO, the term probiotic means "alive microorganisms that, administered in adequate amounts, provide benefit to the health of the host'. The FAO/WHO document giving this definition refers to non-pathogenic microorganisms, lactobacilli and bifidobacteria, present or added to food, which are able to exert beneficial effects to the body.
In recent years, the effect of pathogenic bacterial species on dental implants also has been studied [Tamrakar A.K. et al. J. Oral Biology and Craniofacial Research 2020, 10: 180-183], In fact, an oral dysbiosis can lead to implant loss. Chemotherapy treatments and radiotherapy can also cause oral mucositis (stomatitis), resulting in very painful inflammations and ulcerations which become an easy target for bacterial and viral infections.
According to WHO data, there is a high incidence of periodontal disease among adults, at least in the early stages. For example, in Europe, about 20% of the population in the middle age group (35-44 years old) and up to 40% in the older age group (65-74 years old) suffer from this disease, which is multifactorial. Furthermore, the health of the oral cavity has impacts on the overall well-being of the organism, starting from the prevention of cardiovascular problems [Aguilera, E.M. et al., Cardiovascular Res. 2019, 116: 28-39],
It is possible to promote actions against pathogenic bacteria of the oral microbiota, with preventive and curative effects of periodontal disorders. A possible action is introducing probiotic lactobacilli to partially replace pathogenic microorganisms, with promising results in controlling oral infections [Hoare et al. Microbiol Spectr. 2017, 5: doi: 10.1128/microbiolspec. BAD-0006-2016.]
Lactobacilli are Gram-positive bacteria, they obtain the energy necessary for their survival thanks to a fermentation process of hexose sugars (for example, glucose, mannose, fructose, etc.) by producing lactic acid and ethanol. Other bacteria producing lactic acid from sugars, albeit via a different metabolic pathway, are bifidobacteria. Lactobacilli and
bifidobacteria belong to the group of bacteria defined as "probiotics", which carry out a series of beneficial actions, especially, but not only, in the intestine of Mammals and in particular in Humans. These probiotics secrete several antimicrobial substances, such as enzymes, organic acids, hydrogen peroxide and bacteriocins, and compete with buccal pathogens for mucosal adhesion sites [Meurman J.H. et al. Eur J Oral Sci 2005; 113: 188-1962],
Therefore, to overcome the disorders caused by the pathological effects of microorganisms of the oral cavity, the use of lactic acid bacteria and bifidobacteria represents an alternative and promising therapeutic opportunity, as well as being an effective method for maintaining correct dental and oral cavity health. Probiotic lactobacilli and bifidobacteria can compromise the viability of pathogenic microorganisms through the modulation of the pH and/or the redox potential of the environment in which they live, by stimulating non-specific immune mechanisms and modulating the humoral and cellular immune response [Marco M.L. et al., Curr. Opin. Biotech. 2006, 17: 204-210],
In recent years, to enrich the oral microbiota with beneficial bacteria (oral eubiosis) several probiotics-containing formulations in the form of granules for oral suspension have been developed. There are many probiotic strains with recognized therapeutic properties against periodontal infections, however, the analysis of clinical studies has shown that further research and studies focused on dosages, routes of administration and strains to be used are needed [Vives-Soler A. et al. Med Oral Patol Oral Cir Bucal. 2020; 1 : e161 -7].
Recently it has been shown that Lactobacillus brevis ATCC 4006 may have beneficial effects in the treatment of some oral diseases. This probiotic is currently marketed in an orodispersible tablet formulation, under the name Inersan®. In a group of patients suffering from chronic periodontitis treated with this formulation, an anti-inflammatory effect determined by the composition was found.
Piyush Shah et al. J. Clin. Diagn. Res., 2013, 7: 595-600, describes a clinical study wherein the effect of the probiotic Inersan® administered to patients with periodontitis is compared with the combination of the probiotic with the antibiotic doxycycline, and with the effect determined by the administration of the antibiotic alone. The study has shown that the probiotic composition based on lactobacilli was able to perform a favorable action on gingival inflammation and in preventing the appearance of caries, without the need to take doxycycline and therefore eliminating the problems associated with drug resistance towards antibiotics.
Toiviainen, A. et al. Clin Oral Investig., 2015; 19: 77-83 discloses the use of a tablet formulation comprising Lactobacillus rhamnosus GG and Bifidobacterium animalis subsp. lactis BB-12, with a 4-week treatment in healthy patients. The study has shown that shortterm consumption of L. rhamnosus LGG and B. animalis BB-12 is sufficient to determine a decrease in the amount of bacterial plaque associated with gingival inflammation.
The strain Lactobacillus rhamnosus SP1 (DSM 21690) was used in a study aimed to evaluate the effect of administering this probiotic on improving dental health in a group of 205 preschool children in Chile. The L. rhamnosus SP1 strain is given in freeze-dried form (1 .5 billion of alive lactic ferments) as a food supplement in 150 ml of milk in the afternoon snack consumed at school. Dental plaque analysis at the beginning and at the end of treatment lasting ten months, has shown a slight decrease in caries in the group that received the probiotic (54.4%) compared to the control group (65.8 %), but after two more months without further administration of the probiotic (12 months from the beginning of the test) the carious lesions in the children who had drunk the enriched milk, were significantly lower (9.7%) than in the control group (24.3%) showing that the likelihood of developing caries after the administration of the probiotic was significantly decreased. The study has demonstrated the efficacy of this treatment with probiotics in pediatric patients, in preventing the development of caries, but not of periodontal infections, such as gingivitis and pyorrhea [L’lntegratore Nutrizionale 2017 , 20: 56-57],
The efficacy of a mixture comprising several bacterial strains including Lactobacillus helveticus SP27 (DSM29575) used as an adjuvant in the treatment of some forms of pneumonia resistant to a wide range of antibiotics has been demonstrated [Piatek J. et al. Int. J. Med. Res. Health Sci., 2019, 8: 12-20],
The same probiotic composition, containing more bacterial strains, has also been used in the treatment of persistent forms of enteric infection caused by Salmonella typhimurium. In this case it has been observed that the inhibitory effect of the individual strains varies significantly, Streptococcus thermophilus ST-21 and Lactobacillus helveticus SP27 strains present in the mixture show the strongest inhibitory effect [Piatek J. et al. Beneficial Microbes. 2018; 10: 211 -217], No specific effect against periodontal infections is mentioned in the two Piatek's publications.
The nutraceutical product Kijimea® K53 comprising probiotic strains Lactobacillus rhamnosus SP1 (DSM 21690) and Lactobacillus helveticus SP27 (DSM 29575), together
with other 51 strains of probiotic bacteria, is indicated for use in states of tiredness and fatigue. The composition also includes vitamin B12 and biotin.
Vuotto et al. (Oral Diseases, 2013; 20: 668-674) describes the use of Lactobacillus brevis to prevent the formation of the buccal biofilm caused by Prevotella melaninogenica, one of the causative agents of periodontitis.
WO 2018/169296 discloses mucoadhesive buccal films comprising probiotic bacteria (e.g. Lactobacillus brevis). The films contain gelling agents and are made by drying of highly viscous solutions. Mucoadhesive films for the release of alive lactobacilli represent a suitable dosage form for the treatment of oral cavity disorders but require long production times with consequent loss of vitality during the preparation process and during the storage.
Patent application CN 107865891 describes probiotic compositions, in form of gel, useful for inhibiting the growth of periodontal pathogens and for preventing and treating periodontitis. These probiotics include Lactobacillus acidophilus (10-30%), Streptococcus salivarius M18 (10-50%) and Streptococcus salivarius K12 (20-80%) bacteria, overall in amount from 107 to 1010 CFU/ml, and pharmaceutically acceptable vehicles or excipients, wherein the bacterial suspension is mixed with a matrix comprising 1 -10% modified cellulose-based polymeric gel, in oily carrier, to which hydroxypropyl methylcellulose as bioadhesive material is added, and a silicon-based rheological modifier. The document shows composition stability data for up to six months of storage.
Given the beneficial activity of the use of probiotics in all the inflammations and disorders of the oral cavity, it is useful to have alternative pharmaceutical/nutraceutical compositions that are able to keep probiotics alive and to release them in the mouth in a controlled manner. It is also important that the composition remains adhered to the buccal mucosa and is also accepted by the subjects.
Being able to ensure the presence of probiotics for prolonged periods compared to current formulations that disperse probiotics in few minutes, can ensure a significant therapeutic advantage for the principle that probiotics act against pathogenic bacteria through a competition mechanism. For this reason, it is important to develop formulations including probiotics able of being released alive and active at the site of action for a prolonged time.
Semi-solid dosage forms such as mucoadhesive oral gels have the advantage of ensuring a more intimate contact and an easier and faster dispersion of the active ingredients, the probiotic, its enzymes and pharmacologically active substances, through the oral mucosa.
A composition in the form of a mucoadhesive gel, comprising probiotics in amounts higher than 1x107 CFU/g which are released in a time longer than six hours, has surprisingly been found, and it is the object of the present invention.
The gel is stable at room temperature and is characterized by an extreme ease of administration.
SUMMARY OF THE INVENTION
The object of the invention is a mucoadhesive gel composition comprising: a probiotic in an amount from 1x107 to 1x1015 CFU/g; from 50 to 85% (w/w), with respect to the weight of the final composition, of a dispersing agent selected from the group consisting of: esters of fatty acid (C4-C30) with glycols, lecithins, non-ionic waxes, phospholipids, polaxamers, polyoxy alkyl esters, castor oil derivatives, polyoxyethylene esters of sorbitan and fatty acids, polyglycerides, povidone, stearic acid, esters of stearic acid and glycerin, sorbitan esters, starch, hydroxy stearate, and mixture thereof; from 5 to 20% (w/w), with respect to the weight of the final composition, of a bioadhesive agent selected from the group consisting of: glyceryl monooleate, hydroxypropylmethyl cellulose with viscosity from 750 to 1400 mPa sec in a 2% (w/w) aqueous solution, polycarbophil, polyethylene oxide, carbomers, dextrins, glucans, and mixture thereof; from 10 to 30% (w/w), with respect to the weight of the final composition, of a viscosifying mixture comprising: from 60.0 to 90.0% (w/w), with respect to the weight of said mixture of a viscosifying agent selected from the group consisting of: glyceryl behenate, agar, bentonite, xanthan gum, xyloglucans, hyaluronic acid esters with molecular weight higher than 300KDa,
linseed, acacia gum, arabic gum, alginic acid and its esters, corn starch, colloidal bentonite, lanolin, waxes, beeswax, palmitic acid esters cellulose, ethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, cellulose, myristilic acid, polyvinyl acetate, povidone, alginate, carrageenan, cetostearyl alcohol, chitosan, gelatin, glycerin, type 1 vegetable oil, silica, sucrose, hydroxypropyl methylcellulose with a viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution and mixture thereof; from 10.0 to 40.0% (w/w), with respect to the weight of said mixture, of a substituted silica with linear or branched alkyl groups, optionally including one or more heteroatoms.
The probiotics according to the present invention are preferably selected from the group consisting of: lactobacilli selected from the group consisting of: Lactobacilli salivarus, Lactobacilli brevis, Lactobacilli helveticus, Lactobacilli paracasei, Lactobacilli rhamnosus, Lactobacilli animalis, Lactobacilli reuteri, Lactobacilli plantarum, Lactobacilli acidophilus, Lactobacilli belbrueckir, Bifidobacteria selected from the group consisting of: Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium brevis, Streptococcus thermophilus, and mixtures thereof.
A second aspect of the present invention is to provide a process for the preparation of a mucoadhesive gel composition according to claim 1 comprising the following steps: a. providing said dispersing agent in an amount of 50-85 % (w/w) and adding said viscosifying mixture in an amount of 10-30% (w/w), at a temperature between 50 and 80 °C; b. adding said bioadhesive agent in an amount of 5 to 20% (w/w); c. cooling down to room temperature; d. adding under stirring said probiotics in an amount from 1x107 to 1x1015 CFU/g; and e. aliquoting in a chosen dosage.
A third object of the invention is the use of the mucoadhesive composition for the prevention and treatment of disorders, pathologies and inflammations of the oral cavity, gingivitis, peri- implantitis, periodontitis, stomatitis and caries.
BRIEF DESCRIPTION OF THE FIGURES
Figure 1 : Release of probiotics included in the GEL 6 formulation (AL0005)
• GEL 6/I loaded with B. animalis BCL01 DSM 17741 (1A);
• GEL 6/II loaded with L. reuteri LR92 DSM 26866 (1 B);
• GEL 6/III loaded with L. brevis SP48 DSM 16806 (1 C);
• GEL 6/IV loaded with L. helveticus SP27 DSM 29575 (1 D);
• GEL 6/V loaded with L. rhamnosus SP1 DSM 21690 (1 E);
• GEL 6/VI loaded with L. paracasei LGM S-26420 (1 F).
Figure 2: Release of probiotics (L. rhamnosus SP1 DSM 21690 and L. helveticus SP27 DSM 29575) included in GEL 6A formulation (AL0006).
Figure 3: Release of probiotics (L rhamnosus SP1 DSM 21690, L. helveticus SP27 DSM 29575 and L. paracasei LGM S-26420) included in the GEL 6D formulation (AL0007).
Figure 4: Graph showing the variation over time in the body weight of mice over the 28-day study period.
Figure 5: Graph showing the variation over time in mm of the maxillary alveolar bone in animals over the 28-day treatment period.
DETAILED DESCRIPTION OF THE INVENTION
The present invention relates to a mucoadhesive gel comprising at least one probiotic for the treatment and/or prevention of disorders, pathologies of the oral cavity. The mucoadhesive gel is characterized by releasing the probiotics included in the formulation in a time longer than six hours.
The mucoadhesive gel comprises a dispersing agent in an amount from 50 to 85% (w/w), a viscosifying mixture in an amount from 10 to 30% (w/w), and a bioadhesive agent in an amount from 5 to 20% (w/w), with respect to the total weight of the composition.
The gel may further comprise pharmaceutical excipients such as sweetening, preserving and flavoring agents.
The dispersing agent is selected from the group consisting of: esters of fatty acid (C4-C30) with glycols, lecithins, non-ionic waxes, phospholipids, polyxamers, polyoxy alkyl esters, castor oil derivatives, polyoxyethylene esters of sorbitan and fatty acids, polyglycerides, povidone, stearic acid, esters of stearic acid and glycerin, sorbitan esters, starch, hydroxy stearate, and mixture thereof.
The bioadhesive agent is selected from the group consisting of: glyceryl monooleate, hydroxypropylmethyl cellulose with viscosity from 750 to 1400 mPa sec in a 2% (w/w) aqueous solution, polycarbophil, polyethylene oxide, carbomers, dextrins, glucans, and mixture thereof;
The viscosifying mixture according to the invention comprises: from 60.0 to 90.0% (w/w), with respect to the weight of said mixture of a viscosifying agent selected from the group consisting of: glyceryl behenate, agar, bentonite, xanthan gum, xyloglucans, hyaluronic acid esters with molecular weight higher than 300KDa, linseed, acacia gum, arabic gum, alginic acid and its esters, corn starch, colloidal bentonite, lanolin, waxes, beeswax, palmitic acid esters cellulose, ethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, cellulose, myristilic acid, polyvinyl acetate, povidone, alginate, carrageenan, cetostearyl alcohol, chitosan, gelatin, glycerin, type 1 vegetable oil, silica, sucrose, hydroxypropyl methylcellulose with a viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution and mixture thereof; from 10.0 to 40.0% (w/w), with respect to the weight of said mixture, of a substituted silica with linear or branched alkyl groups, optionally including one or more heteroatoms.
The preferred viscosifying agent is a mixture of viscosifying agents consisting of ethyl cellulose, glyceryl behenate, hydroxypropyl methylcellulose with a viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution.
According to the present invention, the term dispersing agent refers to a compound or a compounds mixture that, added to a composition improving the separation of particles and prevents settling or clumping.
According to the present invention, the term bioadhesive or mucoadhesive agent refers to natural materials that act as adhesives, in particular refers to a material designed to adhere to biological tissue.
According to the present invention, the term viscosifying agent, or thickening agent, refers to a substance that can increase the viscosity of a liquid without substantially changing its other properties.
According to the present invention the preferred heteroatoms are nitrogen, oxygen, sulfur, phosphorus, chlorine, bromine, and iodine, as well as the metals lithium and magnesium.
Preferably the substituted silica is dimethyl silylated silica.
Preferably the viscosifying agent comprises a said substituted silica in an amount from 2.5 % to 5.0 % (w/w), with respect to the weight of the final composition.
Preferably in the mucoadhesive gel composition according to the invention said dispersing agent is in an amount from 60 to 75% (w/w), with respect to the weight of the final composition; said bioadhesive agent is in amount from 5 to 10% (w/w), with respect to the weight of the final composition; said viscosifying mixture is in an amount from 20 to 30% (w/w), with respect to the weight of the final composition.
In a preferred aspect, the mucoadhesive gel composition comprises probiotics in an amount from 1x107 to 1x1015 CFU/g, a dispersing agent consisting of a mixture of esters of fatty acids (C4-C30) with glycols, in an amount from 60 to 75% (w/w) with respect to the total weight of the composition, a viscosifying mixture consisting of ethyl cellulose, glyceryl behenate, substituted silica and hydroxypropyl methylcellulose with a viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution respectively in a weight ratio 1 :0.5: 1 to 1 :1 :5, a bioadhesive agent consisting of hydroxypropyl methylcellulose with viscosity from 750 to 1400 mPa sec in a 2% (w/w) aqueous solution in an amount from 5 to 10% (w/w), relative to the total weight of the composition.
The mucoadhesive gel composition comprises the viscosifying mixture consisting of a mixture of ethyl cellulose, glyceryl behenate, substituted silica and hydroxypropyl methylcellulose with a viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution (Benecell K4M), in a weight ratio from 1 : 0.5: 1 : 1 to 1 : 1 : 5: 10.
The mucoadhesive gel composition is characterized by comprising a mixture of high viscosity hydroxypropyl methylcellulose, in which a hydroxypropyl methylcellulose characterized by producing a viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution and a hydroxypropyl methylcellulose characterized by producing a viscosity from 750 to 1400 mPa sec in a 2% (w/w) aqueous solution, which are respectively in a weight ratio from 0.5: 1 .5 to 1 :5.
In a more preferred embodiment, the mucoadhesive gel composition comprising esters of caprylic and/or capric acid with propylene glycol in an amount from 50.0 to 80.5% (w/w), ethyl cellulose 5.0-10.0% (w/w), glyceryl behenate 2.5-10.0% (w/w), dimethyl silylated silica 2.5-5.0% (w/w), hydroxypropylmethyl cellulose with a viscosity from 750 to 1400 mPa sec in a 2% (w/w) aqueous solution, in an amount from 5 to 20% (w/w), and hydroxypropylmethyl cellulose with viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution, in an amount from 5.0 to 10.0% (w/w), with respect to the final composition.
The mucoadhesive gel composition according to the present invention can also comprise pharmaceutically acceptable excipients such as preserving agents, buffering agents, flavoring agents.
Flavoring agents are selected from the group comprising natural plant, citrus and fruit extracts.
The mucoadhesive gel composition is characterized by being lipophilic and is homogeneous without separation of the oily phase from the gel phase.
The mucoadhesive gel composition according to the invention is characterized by a viscosity measurement between W and 40 mPa sec when a shear stress from 1 to 10 s-1 is applied.
In a particular aspect the viscosity of the formulation is between 14 and 38 mPa sec when a shear stress from 1 to 10 s_1 is applied.
The composition of the mucoadhesive gel is characterized by an adhesion to a mucin layer by more than 70% compared to an aqueous solution.
The mucoadhesive composition offers the advantage of releasing probiotics into the oral cavity in a controlled manner, increasing the therapeutic efficacy with less frequency of
administration. The composition in gel form has the advantage to be easily administered one or more time in a day and well accepted by the subject.
The mucoadhesive gel composition according to the present invention does not contain water or is substantially free of water.
The gel composition includes one or more probiotics, belonging to the lactobacilli and/or bifidobacteria species selected from the group comprising: Lactobacilli salivarus, Lactobacilli brevis, Lactobacilli helveticus, Lactobacilli paracasei, Lactobacilli rhamnosus, Lactobacilli animalis, Lactobacilli reuteri, and bifidobacteria, as for example, Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium brevis and/or their mixtures.
In one embodiment, the mucoadhesive gel composition preferably comprises the probiotics selected from the group comprising: Lactobacillus rhamnosus (DSM 21690), Lactobacillus helveticus (DSM 29575), Lactobacillus paracasei (LGM S-26420), and/or their mixtures, in amounts of 1x109 -1x1017 (CFU/100g).
The probiotics Lactobacillus rhamnosus (DSM 21690), Lactobacillus helveticus (DSM 29575) and Lactobacillus paracasei (LGM S-26420) in amounts of 1x109 -1x1017 (CFU/100g) and/or their mixtures are released in a time from 10 minutes to 6 hours.
In a preferred aspect the unitary composition is reported in Table 1 :
Preferred unitary mucoadhesive gel compositions comprising probiotics are reported in Tables 3 and 4. Table 3
Table 4
The mucoadhesive gel composition according to the invention is characterized by the ability to release probiotic microorganisms in a controlled manner, in a percentage greater than 70%, in a time from ten minutes to six hours, in which the probiotics maintain their vitality.
It has been shown that the gel has a good adhesion to several types of materials, both of non-specific nature, such as filter paper, and polycrystalline bioceramic, a dentin mimicking material.
By in vitro studies it has been shown that the gel allows the release of probiotics from the gel into the mucous membrane of the oral cavity and into the dental biofilm.
It has been shown that the composition is characterized by releasing the probiotics in a solution (artificial saliva), in a time from ten minutes to two hours, in which a percentage greater than 60% of the probiotics are released after 2 hours, and a percentage of the 75% after 5 hours.
In one particular aspect, it has been shown that the mucoadhesive gel composition releases a percentage of L. rhamnosus SP1 (DSM 21690) and L. helveticus SP27 (DSM 29575) equal to 62%, and in a percentage from 60% to 70% after two hours and adheres to the surface of microcrystalline bioceramic, the release percentage remains practically constant from 50% to 70% from ten minutes to six hours.
The percentage of probiotics released from the mucoadhesive gel containing L. rhamnosus SP1 (DSM 21690), L. helveticus SP27 (DSM 29575) and L. paracasei CBA-L87 (LGM S- 26420) and adhered to the surface ranges from 50 to 70% after two hours, and it rises up to 80% after 8 hours. Therefore, the bacteria released from the gel preparation maintain their ability to adhere to the surface and to maintain their vitality for a very long time and such as to allow them to exert their beneficial effect at the application site, up to eight hours after administration, thus favoring a greater distribution and release of probiotics even in the gingival pockets.
The mucoadhesive gel composition includes probiotics selected in the group comprising L. rhamnosus SP1 (DSM 21690), L. helveticus SP27 (DSM 29575) and L. paracasei CBA-L87 (LGM S-26420) and their mixtures, which inhibit the growth of pathogenic bacteria responsible for periodontal infections in the oral microbiome. This effect has been demonstrated in vitro on pathogenic strains responsible for mouth infections/inflammations such as Porphyromonas gingivalis (ATCC 33277), Terponema denticola (ATCC 35045),
Tannarella forsythia (ATCC 43037), Prevotella melaninogenica (ATCC 25845) and Aggregatibacter actinomycetemcomans (ATCC 700685).
In a second aspect of the present invention, it is described the process for the preparation of the mucoadhesive composition as described before, comprising the steps of: a. providing a dispersing agent in an amount of 50-85 % (w/w) and adding a viscosifying mixture in an amount of 10-30% (w/w), at a temperature between 50 and 80 °C; b. adding a bioadhesive agent in an amount of 5 to 20% (w/w); c. cooling down to room temperature; d. adding under slight stirring probiotics in an amount from 1x107 to 1x1015 CFU/g; and e. aliquoting in a chosen dosage form.
Preferably, in the process according to the invention, the dispersing agent is an ester of capric and/or caprylic acid with propylene glycol, in an amount of 50.0 to 80.5% (w/w); the viscosifying mixture is ethyl cellulose, in an amount from 5.0 to 10.0% (w/w), glyceryl behenate in an amount from 2.5 to 10.0% (w/w) hydroxypropyl methylcellulose with viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution from 5.0 to 20.0% (w/w) and dimethyl silylated silica in an amount from 2.0 to 5.0% (w/w); the bioadhesive agent is hydroxypropyl methylcellulose with viscosity from 750 to 1400 mPa- sec in a 2% (w/w) aqueous solution in an amount from 5.0 to 20.0% (w/w); and the probiotics are selected from the group consisting of: L. rhamnosus, L. paracasei, L. reuteri, L. helveticus, L. brevis, L. salivarius, L. plantarum, Streptococcus thermophilus, L. acidophilus, L. belbrueckii, B. longum, B. infantiand B. brevis.
The mucoadhesive gel composition according to the invention is dispensed in tubes of 5, 10, 15, 50 grams and stored at room temperature.
Another object of the present invention is a medical device comprising the mucoadhesive gel comprising probiotics.
The mucoadhesive gel composition according to the invention is stable for at least 6 months, at room temperature, period wherein the viability of the probiotic strains remains unaltered.
The mucoadhesive gel composition according to the invention is useful for the treatment and/or prevention of oral diseases, in the prevention of periodontitis, gingivitis, stomatitis and caries.
In a study on an animal model of periodontitis it has been shown that the composition is effective in preventing damage to the teeth and their loss.
The effectiveness of the formulation according to the invention has been confirmed in a mouse model in which inflammation was induced by ligating the teeth. The mucoadhesive gel comprising probiotics L. rhamnosus SP1 (DSM 21690), L. helveticus SP27 (DSM 29575) and L. paracasei CBA-L87 (LGM S-26420) was found to be significantly effective compared to the gel without probiotics. The composition comprising L. rhamnosus SP1 (DSM 21690) and L. helveticus SP27 (DSM 29575) is effective in preventing tooth loss in a percentage from 80 to 90% compared to the gel without probiotics in which the percentage ranges from 20 to 40 %.
The mucoadhesive gel composition according to the invention is useful for recovering alveolar bone loss which was particularly sensitive in the group treated with the mucoadhesive gel comprising L. rhamnosus SP1 (DSM 21690) and L. helveticus SP27 (DSM 29575), as shown in Figure 5.
The mucoadhesive gel composition according to the invention useful for preventing problems in the oral cavity, such as periodontitis (pyorrhea), halitosis, gingival recession, gum bleeding, abscess and swelling of the gums, pain and difficulty while chewing. The composition is also useful for preventing/treating peri-implantitis, or the bacterial infection that develops around dental implants.
The mucoadhesive gel composition according to the invention can be used in combination with antibiotics, chemotherapy, radiotherapy, immunosuppressants.
The mucoadhesive gel composition according to the invention can be applied to the gums one to five times a day; it is well tolerated and has no toxic or adverse effects either on the mucosa or at a systemic level.
EXAMPLES
Example 1 : PREPARATION OF BUCCAL GEL
Preparations of 100 grams of six gels were obtained by placing in a mixer in the following order: ethyl cellulose and ester of capric and caprylic acid with propylene glycol at a temperature of 85°C. The mixture was kept stirring until homogeneous, then brought to room temperature.
Glyceryl beetate, dimethyl silylated silica (Aerosil® R972), hydroxy-propylmethylcellulose (Benecell K4M) and (Benecell K100M) were added to the six homogeneous mixtures and the final mixtures were kept stirred until homogeneous mixtures were obtained. The unitary compositions are reported in Table 5.
Gel compositions 1 -6 were placed in glass tubes and after 24 hours centrifuged at 3000 rpm for 15 min and their appearance was evaluated: Gel 1 : the oily phase is separated from the gel phase by approximately 50%
Gel 2: the oily phase is separated from the gel phase by about 20%
Gel 3: the oily phase is separated from the gel phase by about 10%
Gel 4: the oily phase is separated from the gel by about 5%
Gel 5: the oily phase is separated from the gel by about 1 %
Gel 6: the gel is homogeneous without separation of the oily phase from the gel phase.
Gel 6 Formulation (AL0005) was chosen for preparations of gel containing probiotics.
Example 2: PREPARATION OF THE GEL COMPOSITION CONTAINING A PROBIOTIC STRAIN
The lyophilized bacteria of one of the probiotic strains were added to an amount of gel equal to 10 grams of GEL 6 obtained as shown in example 1 : B. animalis subsp. lactis BCL01 (DSM 17741 ), Lactobacillus rhamnosus SP 1 (DSM 21690) Lactobacillus reuteri LR92 (DSM 26866), Lactobacillus brevis SP48 (DSM 16806), Lactobacillus helveticus SP27 (DSM 29575), all registered with the Deutsche Organism Braunschweig, Germany, or the lyophilized bacteria of the Lactobacillus paracasei strain (LGM S-26420), deposited at the Belgian Coordinated Collection of Microorganism - BCCM/LMG Bacteria Collection, Laboratory for Microbiology, Ghent University.
Six probiotic gels as reported in Table 6 were obtained.
Example 3: DETERMINATION OF THE RELEASE CAPACITY OF THE SINGLE BACTERIAL STRAINS FROM THE GEL
The amount of bacteria released from the formulation of GEL 6 loaded with bacteria of several strains in single form was evaluated both in physiological solution and in an artificial saliva solution at time intervals of 30 minutes, 2 hours, 5 hours and 8 hours. Through the microbiological analysis performed by the BioTimer, the initial and residual bacterial load in the gels at various time intervals, and in parallel the amount of bacteria released in the two types of solution were determined [Pantanella F. et al. Journal of Microbiological Meth.,
2008, 75: 478-484], In particular, 400 mg of each probiotic gel preparation were divided into 10 tubes, each containing 40 mg of gel, and divided into two series of 5 tubes each. To each of the 5 tubes of a serie, 0.2 ml of artificial saliva solution (8.0 g/L sodium chloride, 2.38 g/L dibasic disodium phosphate, 0.19 g/L monobasic potassium phosphate, pH 6.8), and to each of the 5 tubes of the second series 0.2 ml of physiological solution were added. In Table 7 the release data in artificial saliva up to 5 hours, and in Table 8 the release data in physiological solution up to 8 hours, expressed as CFU/g for the gel and CFU/ml for the solution in which the release took place, are shown.
The amounts of probiotics released by Gels 6/l-VI have shown that in artificial saliva an important amount of L. paracasei (LGM S-26420) is released already after 30 minutes, while in physiological solution the release occurs more slowly. No bacteria are released from gel formulations containing L. brevis SP48 (DSM 16806) and B. animalis BCL01 (DSM 17741) in artificial saliva solution. In physiological solution the formulation containing L. brevis SP48 (DSM 16806) begins to release bacteria from the gel only after 8 hours, the formulation containing B. animalis BCL01 (DSM 17741) begins to release in minimum amounts after two
hours and the maximum release is also in this case after 8 hours. Bacteria of the L. reuteri strain were not very stable in the formulation of GEL 6.
Example 4: PREPARATION OF THE GEL COMPOSITION CONTAINING MIXTURES OF PROBIOTIC STRAINS Based on the results obtained with the probiotic gel preparations containing only one probiotic strain, the gel formulations containing the probiotic strains L. paracasei (LGM S- 26420), L. rhamnosus SP1 (DSM 21690) and L. helveticus SP27 (DSM 29575) in association with each other as indicated in Table 9 were prepared. The preparations were carried out on a 10 grams scale by adding the bacteria in lyophilized form to the preparation 6 of Example 1 . In Table 9 the starting bacterial load of the single strains in lyophilized form and of the probiotic mixtures before being added to GEL 6 is indicated by CFU count and the BioTimer method.
STRAIN ASSOCIATIONS
The amount of bacteria released from GEL 6/l-VI compositions (Example 2) was evaluated in physiological solution at time intervals of 30 min, 2 hours, 5 hours and 8 hours as
described in Example 4. The results obtained for the four compositions are reported in Table 10.
Table 10
The results obtained from the analyses have shown that the probiotics are released in physiological solution from Gel 6/C after 8 hours. The release profile of Gel 6/B is comparable to that of Gel 6/A.
Gel 6/A (AL0006) and Gel 6/D (AL0007) were selected for the preparations on a 100 grams scale. Example 6: DETERMINATION OF THE VISCOSITY OF THE GEL FORMULATIONS
The viscosity of the GEL 1 -6 compositions, prepared according to Example 1 , and of the GEL 6A and GEL 6D compositions, comprising the probiotic consortia and prepared according to Example 4, was measured by the rotational rheometer Kinexus Pro + (Malvern Analytical ), at a temperature of 37 °C depending on the shear stress. Table 11 shows the viscosity values with shear stress equal to 10 s’1.
From the analysis of the rheological properties of the compositions it has been found that the addition of probiotic bacteria to the gel composition does not substantially affect the viscosity of the formulation.
Example 7: DETERMINATION OF MUCOADHESIVENESS
The in vitro determination of the mucoadhesiveness of the GEL 6 formulation, prepared according to example 1 , was carried out using the inert inclined plane method in the presence of a mucin biofilm, compared to an aqueous solution. The test was carried out by sliding the sample on an inert support (steel) covered with a layer of 8% porcine gastric mucin. The adhesion on the mucin layer was evaluated in relation to the adhesion of the same sample on the inclined inert support not covered with mucin. The actual mucoadhesion is determined by the delay in the flow of the sample and in the detachment from the plane caused by the presence of mucin. In order to be considered mucoadhesive, a sample have to demonstrate an adhesion compared to the control without mucin significantly higher than that one demonstrated by water, which interacts with the protein for hygroscopic absorption only.
Two ml of each sample: Gel 6, Gel 6/mucin, water, and water/mucin were placed on the table and let to adhere for 2 minutes. The plane was inclined at 45° and at the end of the run the sample portion was collected and weighed.
The mucoadhesive values obtained are reported in Table 12.
The results of the test carried out on GEL 6 (without probiotics) confirm the mucoadhesive properties of the gel, with a capacity of adhesion to mucin greater than 70%. This
mucoadhesion value is reached after 10 minutes and remains constant for the entire time of the test (60 minutes).
Example 8: PREPARATION OF THE GEL COMPOSITION CONTAINING PROBIOTIC ON AN INDUSTRIAL SCALE
Caprylic/capric triglyceride and ethyl cellulose were placed in a mixer, the temperature was brought to 85-90° C until a homogeneous mixture was obtained. Glyceryl behenate, dimethyl silylated silica and the mixture of hydroxypropyl methylcellulose, (Benecell™ K4M and Benecell™ K100M) were added, and the homogeneous mass was brought to room temperature. Subsequently, blueberry and aloe extracts were added. The mixture was kept under stirring until a homogeneous and finely dispersed gel was obtained. Finally, lemon essential oil and freeze-dried probiotics are added.
The unitary composition of the two gels obtained is reported in Table 13.
The amount of bacteria released from the gel compositions Gel 6A and 6D was evaluated in physiological solution at time intervals of 30 min, 2 hours, 5 hours and 8 hours as described in example 3. The results obtained for the Gel 6A formulation, including the probiotic strains L. rhamnosus and L. helveticus are shown in Table 14 and the results obtained for the GEL 6D formulation, including the probiotic strains L. rhamnosus and L. helveticus and L. paracasei are shown in Table 15.
Example 10 - DETERMINATION OF THE VIABILITY OF THE BACTERIA RELEASED FROM THE GEL IN SIMULATED SALIVARY
The ability of the probiotic strains released by the gel to remain viable for a prolonged time at the administration site, for example, the oral cavity, was evaluated by means of an in vitro test and by comparing the recovery of probiotic strains in MRD solution (Maximum Recovery Diluent) and in SS (artificial saliva). MRD (enzymatic digest of casein or peptone 1 g/L, sodium chloride 8.5 g/L) is a protective and isotonic diluent for microbiological examination indicated by the ISO 6887 standard, its composition promotes maximum recovery of the
microorganisms present in an initial suspension and in decimal dilutions of test samples [Charteris W P. et al. J. Applied Microbiology, 1998, 759-768],
An amount equal to 1 gram of each of the two Gels 6A or Gel 6D was added to a volume of 99 ml of MRD, Biolife. The sample was shaken manually, or mechanically, to ensure a uniform distribution of microorganisms. One ml of the obtained suspension was transferred to a tube containing 9 ml of diluent for serial decimal dilutions. An aliquot of known volume of the initial suspension and its serial dilutions was plated on MRS agar plates (Man, Rogosa and Sharpe), selective medium used for the isolation and cultivation of Lactobacillus sp. from clinical samples, food and dairy products in accordance with ISO/FDIS 15214. The plates were incubated at 37 °C for 2 and 5 hours and then the colonies grown on the plates corresponding to the alive colonies released from the gel were counted. At the same time, the same procedure was carried out by adding an amount equal to 1 gram of each of the two 6A or 6D gels to a volume of 99 ml of artificial saliva (8.0 g/L sodium chloride, 2.38 g/L dibasic sodium phosphate, 0.19 g/L monobasic potassium phosphate, pH 6.8). The results of this test are shown in Table 16.
The obtained data demonstrate that the bacteria of both associations of probiotics released from the gel maintain their viability up to 5 hours under the conditions that simulate the
environment of the oral cavity suspended in the saliva solution at a level slightly lower than those considered to be the optimal conditions for the recovery of the growth of a microorganism after stressful conditions.
Example 11 - DETERMINATION OF THE VIABILITY OF THE BACTERIA RELEASED BY THE GEL ADHERING TO A SURFACE OF A NON-SPECIFIC NATURE
The viability of the probiotic bacteria released from the gel and adhered to a surface of a non-specific nature, such as filter paper, was evaluated using an amount equal to 1 gram of each of the two gels: Gel 6A and Gel 6D diluted respectively in a volume of 99 ml of MRD (Maximum Recovery Diluent) Biolife, (enzymatic digest of casein or peptone 1 g/L, sodium chloride 8.5 g/L) or in SS (artificial saliva) (8.0 g/L sodium chloride, 2.38 g/L dibasic sodium phosphate, 0.19 g/L monobasic potassium phosphate, pH 6.8). For each suspension, decimal serial dilutions were made as described in Example 8. An aliquot of known volume of each initial suspension and its serial dilutions was placed in contact with a sterile filter paper disk and coated with MRD or SS, depending on the dilution medium initially used, for 2 and 5 hours. At the end of the time the filter paper discs were removed with sterile tweezers and placed on an agar plate with growth medium where they were left and incubated at 37 °C for 72 hours. After incubation, the number of colonies grown on the plates deriving from the bacteria adhered to the filter paper and corresponding to the bacteria remained viable after non-specific adhesion was counted.
Table 17 shows the obtained values expressed as Log CFU.
The data show that the viability of probiotic strains released from the gel into a liquid vehicle, such as saliva, or released and adhered to a surface, albeit non-specific, remains substantially the same for a period of time up to 5 hours.
Example 12 - DETERMINATION OF GEL ADHESION TO POLYCRYSTALLINE BIOCERAMIC
The adhesive property of the bacteria released from the gels was determined using a [3- tricalcium phosphate ([3-TCP) disc model; 3D, Biotek, according to what is described in Honglue T et al. Biomaterials 2012, 33: 365-77.
An amount equal to 1 gram of each preparation of Gel 6A or Gel 6D was diluted in MRD solution (Maximum Recovery Diluent, Biolife) and 1 gram was diluted in artificial saliva solution (8.0 g/L sodium chloride, 2.38 g/L dibasic sodium phosphate, 0.19 g/L monobasic potassium phosphate, pH 6.8), until a bacterial concentration of approximately 1x106 CFU/ml is obtained for each diluted gel suspension. [3-TCP Discs were immersed for 2 and 5 hours in 1 ml of each diluted gel suspension, either in MRD or in SS, at 37 °C. After 2 and 5 hours the discs were recovered and placed in a tube containing 9 ml of diluent (MRD or SS) depending on the one initially used. The bacteria adhered to each disk were removed by immersing the tubes in an ultrasonic bath followed by a short vortexing to evenly distribute the bacteria. Starting from the obtained suspensions, serial decimal dilutions in same dilution medium (MRD or SS) were made and then they were plated on agar plates and incubated at 37 °C for 24 hours. In order to get a measure of the bacteria adhering to the surface of the [3-tricalcium phosphate disk the number of colonies grown on the plates was determined.
The percentage of adhesion of probiotics on the surface of the tricalcium [3-phosphate disk is calculated using the formula:
P = ([1/ M) * 100 wherein:
P represents the percentage of adhesion of the mixture of bacteria to the [3-TCP disc 3D Biotek;
[i represents the number of alive bacteria of the analyzed gel bound to the [3-TCP disc 3D Biotek expressed as a logarithmic value;
M represents the number of alive bacteria of the analyzed gel expressed as a logarithmic value of the total suspension load at T = 0.
The results obtained are reported in Table 18.
Example 13: DETERMINATION OF EFFICACY OF THE MUCOADHESIVE GEL COMPOSITION
The efficacy of the gel composition comprising the probiotic strains L. paracasei (LGM S- 26420), L. rhamnosus SP1 (DSM 21690) and L. helveticus SP27 (DSM 29575) was determined in a mouse model of periodontitis induced by tooth ligation, as described by Abe T. and Hajishengallis G. in Optimization of the ligature-induced periodontitis model in mice, Journal of Immunological Methods 2013, 394, 49-54.
Sixty C57BI/6 male mice, 9-10 weeks of age, were fed ad libitum with sterile food and water. On Day "0" the second maxillary molar tooth of the mice, mildly anesthetized, with a
combination of Tiletamine and Xylazine (respectively, 25 mg/kg and 4 mg/kg), was tied with a 5-0 non-absorbable silk surgical suture, to induce inflammation of the periodontium. The mice were divided into four groups of 15 animals per group:
Group 1 . Ligature of the molar. No-treatment
Group 2. Molar ligation + 6A Gel treatment [L. rhamnosus SP1 (DSM 21690) and L. helveticus SP27 (DSM 29575)]
Group 3. Molar ligation + 6D Gel treatment [L. paracasei (LGM S-26420), L. rhamnosus SP1 (DSM 21690) and L. helveticus SP27 (DSM 29575)]
Group 4. Molar ligation + treatment with Gel 6 (No-probiotic bacteria)
Starting from Day “1” the mice of Groups 2-4, under anesthesia, were treated daily, 5 days a week, for three weeks, with the corresponding Gels. Gels were applied in the late afternoon. Subsequently, the animals were left without water for an hour, and then overnight fasted but with free access to water. Three animals per group were sacrificed on day "8", day "15" and day "22". The remaining six animals were sacrificed on day “29”, after one week without Gel treatment.
In the various samples obtained, the loss of alveolar bone was evaluated with respect to the height of the bone in the unbound counterpart, furthermore, the amount of the gingival myeloperoxidase (MPO) enzyme was determined. Traditionally, myeloperoxidase acts as a bactericide by catalyzing the reaction of superoxide ions O2 produced by polymorph-nucleated leukocytes during phagocytosis, creating cytotoxic compounds which, in addition to favor the killing of bacteria and of other pathogens, can perform a significant pro-inflammatory action, and directly contribute to tissue damage in the body. The increase in its presence in saliva is an indicator of the presence of inflammatory phenomena of the mucous membranes or gingival tissue. On all animals a general clinical evaluation was also performed, and the body weight was checked and the loss of the bonded tooth was observed. The latter data is shown in Table 19.
Table 19
The results of the analysis of the variation in mm of the maxillary alveolar bone in animals in the treatment period of 28 days are shown in Figure 5.
Example 14: DETERMINATION OF THE STABILITY OF THE GEL COMPOSITION
The stability of the two gels was evaluated by determining the bacterial load detected in the two formulations stored at room temperature for three and six months. The data are reported in Table 20.
The number of bacterial counts of the two formulations does not undergo alteration and remains substantially unchanged after six months.
Claims
adhesive gel composition comprising: a probiotic in an amount from 1x107 to 1x1015 CFU/g; from 50 to 85% (w/w), with respect to the weight of the final composition, of a dispersing agent selected from the group consisting of: esters of fatty acid (C4- C30) with glycols, lecithins, non-ionic waxes, phospholipids, polaxamers, polyoxy alkyl esters, castor oil derivatives, polyoxyethylene esters of sorbitan and fatty acids, polyglycerides, povidone, stearic acid, esters of stearic acid and glycerin, sorbitan esters, starch, hydroxy stearate, and mixture thereof; from 5 to 20% (w/w), with respect to the weight of the final composition, of a bioadhesive agent selected from the group consisting of: glyceryl monooleate, hydroxypropylmethyl cellulose with viscosity from 750 to 1400 mPa sec in a 2% (w/w) aqueous solution, polycarbophil, polyethylene oxide, carbomers, dextrins, glucans, and mixture thereof; from 10 to 30% (w/w), with respect to the weight of the final composition, of a viscosifying mixture comprising: from 60.0 to 90.0% (w/w), with respect to the weight of said mixture of a viscosifying agent selected from the group consisting of: glyceryl behenate, agar, bentonite, xanthan gum, xyloglucans, hyaluronic acid esters with molecular weight higher than 300KDa, linseed, acacia gum, arabic gum, alginic acid and its esters, com starch, colloidal bentonite, lanolin, waxes, beeswax, palmitic acid esters cellulose, ethyl cellulose, calcium carboxymethyl cellulose, sodium carboxymethyl cellulose, cellulose, myristilic acid, polyvinyl acetate, povidone, alginate, carrageenan, cetostearyl alcohol, chitosan, gelatin, glycerin, type 1 vegetable oil, silica, sucrose, hydroxypropyl methylcellulose with a viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution and mixture thereof; from 10.0 to 40.0% (w/w), with respect to the weight of said mixture, of a substituted silica with linear or branched alkyl groups, optionally including one or more heteroatoms.
- 33 - The composition according to claim 1 , wherein the probiotic is selected from the group consisting of: lactobacilli selected from the group consisting of: Lactobacilli salivarus, Lactobacilli brevis, Lactobacilli helveticus, Lactobacilli paracasei, Lactobacilli rhamnosus, Lactobacilli animalis, Lactobacilli reuteri, Lactobacilli plantarum, Lactobacilli acidophilus, Lactobacilli belbrueckir, Bifidobacteria selected from the group consisting of: Bifidobacterium longum, Bifidobacterium infantis, Bifidobacterium brevis, Streptococcus thermophilus, and mixtures thereof. The composition according to one or more of preceding claims, wherein said dispersing agent is in an amount from 60 to 75% (w/w), with respect to the weight of the final composition; said bioadhesive agent is in amount from 5 to 10% (w/w), with respect to the weight of the final composition; said viscosifying mixture is in an amount from 20 to 30% (w/w), with respect to the weight of the final composition. The composition according to one or more of preceding claims, wherein the viscosifying agent comprises said substituted silica in an amount from 2.5 % to 5.0 % (w/w), with respect to the weight of the final composition. The composition according to one or more of preceding claims, wherein said viscosifying mixture comprises ethyl cellulose, glyceryl behenate, substituted silica and hydroxypropyl methylcellulose with a viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution, in a weight ratio respectively from 1 :0.5: 1 : 1 to 1 : 1 :5: 10. The composition according to one or more of preceding claims, wherein said substituted silica is dimethyl silylated silica. The composition according to one or more of preceding claims, comprising esters of caprylic and/or capric acid with propylene glycol in an amount from 50.0 to 80.5% (w/w), ethyl cellulose 5.0-10.0% (w/w), glyceryl behenate 2.5-10.0% (w/w), dimethyl silylated silica 2.5-5.0% (w/w), hydroxypropyl methylcellulose with a viscosity from 750 to 1400 mPa sec in a 2% (w/w) aqueous solution, in an amount from 5 to 20% (w/w), and hydroxypropyl methylcellulose with viscosity from 75000 to 140000
mPa sec in a 2% (w/w) aqueous solution, in an amount from 5.0 to 10.0% (w/w), with respect to the final composition. The composition according to one or more of preceding claims, characterized by a viscosity value from 10 to 40 mPa sec, when applied a shear stress from 1 to 10 s-1. A mucoadhesive gel composition according to one or more of preceding claims, comprising:
- Lactobacilli 1x109 -1x1017 CFU/100g;
- Ester of capric acid and/or caprylic acid with propylene glycol: 70.1 % (w/w);
- Ethyl cellulose: 5.0% (w/w);
- Glyceryl behenate: 2.6% (w/w);
- Dimethyl silylated silica: 3.1 % (w/w);
- Hydroxypropyl methylcellulose with viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution: 11 .7% (w/w);
- Hydroxypropyl methylcellulose with viscosity from 750 to 1400 mPa sec in a 2% (w/w) aqueous solution: 7.0% (w/w);
- Natural extracts: 0.6% (w/w). The composition according to claim 9, wherein said lactobacilli is selected from the group consisting of: Lactobacillus rhamnosus (DSM 21690), Lactobacillus helveticus (DSM 29575), Lactobacillus paracasei (LGM S-26420), and mixture thereof, in an amount of 1x109 -1x1017 CFU/100g. A mucoadhesive gel composition according to claim 1 , comprising:
- Lactobacillus rhamnosus SP-1 (DSM 21690) 1x109-1x1017 CFU/100 g;
- Lactobacillus helveticus SP-27 (DSM 29575) 1x109-1x1017 CFU/100 g;
- Ester of capric and/or caprylic acid with propylene glycol: 70.1 %;
- Ethyl cellulose: 5.0 % (w/w);
- Glyceryl behenate: 2.6 % (w/w);
- Dimethyl silylated silica: 3.1 % (w/w);
- Hydroxypropyl methylcellulose with viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution: 11 .7% (w/w);
- Hydroxypropyl methylcellulose with viscosity from 750 to 1400 mPa sec in a 2% (w/w) aqueous solution: 7.0% (w/w);
- Natural extracts: 0.6% (w/w). A mucoadhesive gel composition according to claim 1 , comprising:
- Lactobacillus rhamnosus SP-1 (DSM 21690) 1x109-1x1017 CFU/100 g;
- Lactobacillus helveticus SP-27 (DSM 29575) 1x109-1x1017 CFU/100 g;
- Lactobacillus paracasei (LGM S-26420) 1x109-1x1017 CFU/100 g;
- Ester of capric and/or caprylic acid with propylene glycol: 70.1 %;
- Ethyl cellulose: 5.0 % (w/w);
- Glyceryl behenate: 2.6 % (w/w);
- Dimethyl silylated silica: 3.1 % (w/w);
- Hydroxypropyl methylcellulose with viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous solution: 11 .7% (w/w);
- Hydroxypropyl methylcellulose with viscosity from 750 to 1400 mPa sec in a 2% (w/w) aqueous solution: 7.0% (w/w);
- Natural extracts: 0.6% (w/w). A process for the preparation of a mucoadhesive gel composition according to claim
1 comprising the following steps: a. providing said dispersing agent in an amount of 50-85 % (w/w) and adding said viscosifying mixture in an amount of 10-30% (w/w), at a temperature between 50 and 80 °C; b. adding said bioadhesive agent in an amount from 5 to 20% (w/w); c. cooling down to room temperature; d. adding under stirring said probiotics in an amount from 1x107 to 1x1015 CFU/g; e. aliquoting in a chosen dosage form. The process according to claim 13, wherein:
- said dispersing agent is an ester of capric and/or caprylic acid with propylene glycol, in an amount from 50.0 to 80.5% (w/w);
- said viscosifying mixture is ethyl cellulose, in an amount of 5.0 to 10.0% (w/w), glyceryl behenate in an amount of 2.5 to 10.0% (w/w) hydroxypropyl methyl cellulose with viscosity from 75000 to 140000 mPa sec in a 2% (w/w) aqueous
- 36 - solution from 5.0 to 20.0% (w/w) and dimethyl silylated silica in an amount from 2.0 to 5.0% (w/w);
- said bioadhesive agent is hydroxypropyl methyl cellulose with viscosity from 750 to 1400 mPa sec in a 2% (w/w) aqueous solution in an amount from 5.0 to 20.0% (w/w);
- said probiotics are selected from the group consisting of: L. rhamnosus, L. paracasei, L. reuteri, L. helveticus, L. brevis, L. salivarius, L. plantarum, Streptococcus thermophilus, L. acidophilus, L. belbrueckii, B. longum, B. infanti and B. brevis, in lyophilic or liquid form in an amount from 1x107 to 1x1015 CFU/g. A gel composition according to claim 1 for use in the prevention and/or treatment of disorders and pathologies of the oral cavity selected from gingivitis, periimplantitis, periodontitis, caries, inflammation, stomatitis.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
IT102021000001169 | 2021-01-27 | ||
IT102021000001169A IT202100001169A1 (en) | 2021-01-27 | 2021-01-27 | BUCCAL MUCOADHESIVE GEL CONTAINING PROBIOTICS FOR USE IN THE PREVENTION AND TREATMENT OF PERIODONTAL DISEASES. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022161893A1 true WO2022161893A1 (en) | 2022-08-04 |
Family
ID=75111854
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/EP2022/051430 WO2022161893A1 (en) | 2021-01-27 | 2022-01-24 | Buccal mucoadhesive gel containing probiotics for use in the prevention and treatment of periodontal diseases. |
Country Status (2)
Country | Link |
---|---|
IT (1) | IT202100001169A1 (en) |
WO (1) | WO2022161893A1 (en) |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3117822A1 (en) * | 2015-07-17 | 2017-01-18 | AB-Biotics, S.A. | Self-film-forming composition for oral care |
CN107865891A (en) | 2017-11-06 | 2018-04-03 | 四川大学 | A kind of probiotic composition, preparation, bacterium mud and purposes |
WO2018169296A1 (en) | 2017-03-15 | 2018-09-20 | Bioeleven Co., Ltd. | Mucoadhesive devices for the release of probiotics and for the maintenance of their enzyme activities |
-
2021
- 2021-01-27 IT IT102021000001169A patent/IT202100001169A1/en unknown
-
2022
- 2022-01-24 WO PCT/EP2022/051430 patent/WO2022161893A1/en active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP3117822A1 (en) * | 2015-07-17 | 2017-01-18 | AB-Biotics, S.A. | Self-film-forming composition for oral care |
WO2018169296A1 (en) | 2017-03-15 | 2018-09-20 | Bioeleven Co., Ltd. | Mucoadhesive devices for the release of probiotics and for the maintenance of their enzyme activities |
CN107865891A (en) | 2017-11-06 | 2018-04-03 | 四川大学 | A kind of probiotic composition, preparation, bacterium mud and purposes |
Non-Patent Citations (22)
Title |
---|
"AEROSIL R 972 ; Hydrophobic Fumed Silica", INTERNET CITATION, 1 February 2008 (2008-02-01), pages 1 - 2, XP002730765, Retrieved from the Internet <URL:http://www.novochem.ro/letoltes/aerosil%20r%20972%20en.pdf> [retrieved on 20141008] * |
ABE T.HAJISHENGALLIS G.: "Optimization of the ligature-induced periodontitis model in mice", JOURNAL OF IMMUNOLOGICAL METHODS, vol. 394, 2013, pages 49 - 54, XP028672934, DOI: 10.1016/j.jim.2013.05.002 |
AGUILERA, E.M. ET AL., CARDIOVASCULAR RES, vol. 116, 2019, pages 28 - 39 |
ANONYMOUS: "Product information Aerosil R972 Pharma", 1 May 2019 (2019-05-01), XP055851165, Retrieved from the Internet <URL:https://www.palmerholland.com/getmedia/40883c34-9b85-4ec5-a58e-d86db6acd46d/MITM12372_1> [retrieved on 20211013] * |
CHARTERIS W P. ET AL., J. APPLIED MICROBIOLOGY, 1998, pages 759 - 768 |
E. SONESSON: "Investigation of Probiotic Organogel Formulations for use in Oral Health", LINNAEUS UNIVERSITY - DEGREE PROJECT WORK, 1 January 2013 (2013-01-01), pages 1 - 26, XP055723337, Retrieved from the Internet <URL:http://www.diva-portal.org/smash/get/diva2:643164/FULLTEXT02.pdf> [retrieved on 20200818] * |
HOARE ET AL., MICROBIOL SPECTR, vol. 5, 2017 |
HONGLUE T ET AL., BIOMATERIALS, vol. 33, 2012, pages 365 - 77 |
KIBBE A H ED - KIBBE A H (ED): "Handbook of Pharmaceutical Excipients, Colloidal Silicon Dioxide", 31 December 2000, HANDBOOK OF PHARMACEUTICAL EXCIPIENTS, AMERICAN PHARMACEUTICAL ASSOC. [U.A.], WASHINGTON, DC; US, PAGE(S) 143 - 145, ISBN: 978-0-85369-381-9, XP002577667 * |
L'LNTEGRATORE NUTRIZIONALE, vol. 20, 2017, pages 56 - 57 |
MARCO M.L. ET AL., CURR. OPIN. BIOTECH., vol. 17, 2006, pages 204 - 210 |
MEURMAN J.H. ET AL., EUR J ORAL SCI, vol. 113, 2005, pages 188 - 1962 |
PANTANELLA F. ET AL., JOURNAL OF MICROBIOLOGICAL METH, vol. 75, 2008, pages 478 - 484 |
PIATEK J. ET AL., BENEFICIAL MICROBES, vol. 10, 2018, pages 211 - 217 |
PIATEK J. ET AL., INT. J. MED. RES. HEALTH SCI., vol. 8, 2019, pages 12 - 20 |
PIYUSH SHAH ET AL., J. CLIN. DIAGN. RES., vol. 7, 2013, pages 595 - 600 |
RINKEE MOHANTY ET AL., J FAMILY MED PRIM CARE, vol. 8, 2019, pages 3480 - 3486 |
SELWIZ R.H. ET AL., LANCET, vol. 369, 2007, pages 51 - 59 |
TAMRAKAR A. K. ET AL., J. ORAL BIOLOGY AND CRANIOFACIAL RESEARCH, vol. 10, 2020, pages 180 - 183 |
TOIVIAINEN, A. ET AL., CLIN ORAL INVESTIG, vol. 19, 2015, pages 77 - 83 |
VIVES-SOLER A. ET AL., MED ORAL PATOL ORAL CIR BUCAL, vol. 1, 2020, pages e161 - 7 |
VUOTTO ET AL., ORAL DISEASES, vol. 20, 2013, pages 668 - 674 |
Also Published As
Publication number | Publication date |
---|---|
IT202100001169A1 (en) | 2022-07-27 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6043325B2 (en) | Formulation of lactic acid bacteria and its use for the prevention and / or treatment of infectious diseases and inflammation | |
JP5879349B2 (en) | Probiotic composition for oral hygiene | |
Bizzini et al. | Probiotics and oral health | |
JP4203855B2 (en) | Live bacterial preparations containing lactic acid bacteria as active ingredients and foods containing lactic acid bacteria | |
US20140065218A1 (en) | Novel lactic acid bacteria and compositions containing them against bacterial colds | |
Gungor et al. | Probiotics: can they be used to improve oral health? | |
JP2009522330A (en) | Oral health promoting products that stimulate microbial growth | |
JP2019502397A (en) | Probiotics that change the composition of oral biofilms | |
CN108553406B (en) | Composition, application thereof and oral preparation with function of improving oral health | |
Chandra et al. | Effect of a locally delivered probiotic-prebiotic mixture as an adjunct to scaling and root planing in the management of chronic periodontitis | |
Cannon | A review of probiotic therapy in preventive dental practice | |
WO2022161893A1 (en) | Buccal mucoadhesive gel containing probiotics for use in the prevention and treatment of periodontal diseases. | |
do Nascimento et al. | Nutritional influences on oral infections: the oral microbiota modulation | |
JP2012092094A (en) | Oral cavity composition containing lactic bacterium in fats and oils | |
Nadelman et al. | The Effect of Probiotics on Oral Health | |
Prathoshni et al. | Significance of probiotics in periodontal therapy: A short review. | |
Nair et al. | PROBIOTICS: A NOVEL NATURAL THERAPY FOR ORAL HEALTH. | |
Patel et al. | Probiotics and its implication in Oral health | |
Acharya | Probiotics: current knowledge update | |
Suchi et al. | Probiotics and Oral Health: A Review | |
CN113316396B (en) | Saccharomyces cerevisiae Bradyke variety strain for treating oral cavity infectious diseases | |
Chung | Studies on the Oral Disease Improvement Effects of Probiotics: A Review. | |
Sonawane et al. | Probiotics: The Nano Soldiers for Periodontium | |
Stamatova et al. | Lactic Acid Bacteria and Oral Health | |
Patel et al. | Probiotics and its insinuation in oral health |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 22702223 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 22702223 Country of ref document: EP Kind code of ref document: A1 |